<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JIC</journal-id>
<journal-id journal-id-type="hwp">spjic</journal-id>
<journal-id journal-id-type="nlm-ta">J Intensive Care Med</journal-id>
<journal-title>Journal of Intensive Care Medicine</journal-title>
<issn pub-type="ppub">0885-0666</issn>
<issn pub-type="epub">1525-1489</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0885066610393634</article-id>
<article-id pub-id-type="publisher-id">10.1177_0885066610393634</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Analytic Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Posterior Reversible Encephalopathy Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Staykov</surname>
<given-names>Dimitre</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0885066610393634">1</xref>
<xref ref-type="corresp" rid="corresp1-0885066610393634"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schwab</surname>
<given-names>Stefan</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0885066610393634">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0885066610393634"><label>1</label>Neurology Department, University of Erlangen–Nuremberg, Germany</aff>
<author-notes>
<corresp id="corresp1-0885066610393634">Dimitre Staykov, Neurology Department, University of Erlangen–Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany. Email: <email>dimitre.staykov@uk-erlangen.de</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>1</issue>
<fpage>11</fpage>
<lpage>24</lpage>
<history>
<date date-type="received">
<day>4</day>
<month>2</month>
<year>2010</year>
</date>
<date date-type="received">
<day>30</day>
<month>4</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>4</day>
<month>6</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Posterior reversible encephalopathy syndrome (PRES) is characterized by headache, altered mental status, visual disturbances, and seizures. Radiological features typically include edema of the posterior cerebral regions, especially of the parietooccipital lobes. Atypical imaging features, such as involvement of anterior cerebral regions, deep white matter, and the brain stem are also frequently seen. Vasoconstriction is common in vascular imaging. Different conditions have been associated with PRES, but toxemia of pregnancy, solid organ or bone marrow transplantation, immunosuppressive treatment, cancer chemotherapy, autoimmune diseases, and hypertension are most commonly described. The pathophysiology of PRES is unclear and different hypotheses are being discussed. Posterior reversible encephalopathy syndrome is best managed by monitoring and treatment in the setting of a neurointensive care unit. The prognosis is usually benign with complete reversal of clinical symptoms within several days, when adequate treatment is immediately initiated. Treatment of severe hypertension, seizures, and withdrawal of causative agents represent the hallmarks of specific therapy in PRES. Delay in diagnosis and treatment may lead to permanent neurological sequelae. Therefore, awareness of PRES is of crucial importance for the intensivist.</p>
</abstract>
<kwd-group>
<kwd>posterior reversible encephalopathy syndrome</kwd>
<kwd>reversible posterior leukoencephalopathy syndrome</kwd>
<kwd>hypertensive encephalopathy</kwd>
<kwd>eclampsia</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0885066610393634">
<title>Introduction</title>
<p>The term reversible posterior leukoencephalopathy syndrome (RPLS) was first used in 1996 by Hinchey et al<sup><xref ref-type="bibr" rid="bibr1-0885066610393634">1</xref></sup> to describe a condition characterized by transient headache, altered mental functioning, seizures, and loss of vision associated with findings of predominantly posterior leukoencephalopathy on imaging studies. In this case series of 15 patients, RPLS was associated with immunosuppressive or interferon therapy, eclampsia, renal disease, or autoimmune diseases.<sup><xref ref-type="bibr" rid="bibr1-0885066610393634">1</xref></sup> The newly coined term RPLS, however, basically described an already known condition. The same clinical picture with findings of elevated mean arterial pressure (MAP) and similar radiological features was known as the hypertensive encephalopathy syndrome (HTE).<sup><xref ref-type="bibr" rid="bibr2-0885066610393634">2</xref><xref ref-type="bibr" rid="bibr3-0885066610393634"/>–<xref ref-type="bibr" rid="bibr4-0885066610393634">4</xref></sup> Meanwhile the association of hypertension with RPLS is well documented, but hypertension is not always present in such patients, as the case series of Hinchey et al already demonstrates—3 of the 15 cases did not show episodes of elevated blood pressure. Particularly in patients treated with immunosuppressive therapy hypertension may be absent.<sup><xref ref-type="bibr" rid="bibr1-0885066610393634">1</xref></sup> Therefore, the older term HTE seems indeed too restrictive for an appropriate naming. The newly introduced name RPLS has, however, also begun to cause controversy immediately after its publication.<sup><xref ref-type="bibr" rid="bibr5-0885066610393634">5</xref></sup> By now, an extensive body of literature on the syndrome has accumulated, and the term, including its “R,” “P,” and “L” parts, has been increasingly considered misleading for different reasons. First, as cases with nonreversible lesions and neurological deficits have been reported, names like “occipital−parietal encephalopathy,”<sup><xref ref-type="bibr" rid="bibr6-0885066610393634">6</xref></sup> or “potentially reversible encephalopathy syndrome”<sup><xref ref-type="bibr" rid="bibr7-0885066610393634">7</xref>,<xref ref-type="bibr" rid="bibr8-0885066610393634">8</xref></sup> have been suggested to be more appropriate. The term “reversible” is still accepted by majority of authors as a part of the name of the condition, provided that it is supposed to suggest the reversibility of symptoms with adequate therapy, and should not imply, that lesions and clinical deficits must always resolve completely. Second, although the posterior localization of the lesions on imaging is most often seen, brain regions other than the occipitoparietal lobes are reported to be very frequently affected.<sup><xref ref-type="bibr" rid="bibr9-0885066610393634">9</xref></sup> Third, it has been shown, that the lesions on neuroimaging are not restricted to the white matter, as indicated by “<italic>leuko</italic>encephalopathy”. Although the linguistic debate surrounding the name of the syndrome has not been closed yet and different alternatives are still being used, over the last years the name RPLS has been increasingly replaced by “posterior reversible encephalopathy syndrome” (PRES).<sup><xref ref-type="bibr" rid="bibr10-0885066610393634">10</xref></sup> As the latter term better reflects the meanwhile increased knowledge about this condition and is widely accepted to be most appropriate, it will be further used in the present review.</p>
</sec>
<sec id="section2-0885066610393634">
<title>Clinical and Laboratory Characteristics of PRES</title>
<p>The clinical picture of PRES includes several typical features: seizures, an acute encephalopathy syndrome, and visual disturbances.</p>
<p>Seizures commonly represent the first clinical manifestation of the syndrome and are the most frequently seen symptoms in PRES.<sup><xref ref-type="bibr" rid="bibr11-0885066610393634">11</xref>,<xref ref-type="bibr" rid="bibr12-0885066610393634">12</xref></sup> Seizures are generalized in the majority of cases but may also have a focal onset with following secondary generalization. Multiple seizures are even more frequent and status epilepticus (SE) may also occur.<sup><xref ref-type="bibr" rid="bibr11-0885066610393634">11</xref><xref ref-type="bibr" rid="bibr12-0885066610393634"/>–<xref ref-type="bibr" rid="bibr13-0885066610393634">13</xref></sup> The acute encephalopathy syndrome manifests with confusion, headache, vomiting, and altered consciousness from somnolence and lethargy to stupor and coma.<sup><xref ref-type="bibr" rid="bibr1-0885066610393634">1</xref>,<xref ref-type="bibr" rid="bibr6-0885066610393634">6</xref>,<xref ref-type="bibr" rid="bibr10-0885066610393634">10</xref>,<xref ref-type="bibr" rid="bibr11-0885066610393634">11</xref></sup> Episodes of agitation may alternate with lethargic conditions. Severe disturbances of consciousness, especially after seizures, may result in intubation and mechanical ventilation, which was necessary in 39% of PRES cases in a recently reported larger case series.<sup><xref ref-type="bibr" rid="bibr11-0885066610393634">11</xref></sup> Visual disturbance in PRES varies from blurred vision to hemianopsia and complete cortical blindness.<sup><xref ref-type="bibr" rid="bibr11-0885066610393634">11</xref>,<xref ref-type="bibr" rid="bibr13-0885066610393634">13</xref></sup> In such cases, denial of cortical blindness (Anton syndrome) may be observed.<sup><xref ref-type="bibr" rid="bibr1-0885066610393634">1</xref></sup> Other focal neurological signs such as paresis or sensory deficits have also been reported.<sup><xref ref-type="bibr" rid="bibr14-0885066610393634">14</xref></sup> Symptoms may develop acutely, or gradually over a period of several days.<sup><xref ref-type="bibr" rid="bibr14-0885066610393634">14</xref></sup> Blood pressure is normal or only minimally elevated on symptom onset in 20% to 30% of the patients.<sup><xref ref-type="bibr" rid="bibr14-0885066610393634">14</xref></sup> In the remaining 70% to 80%, hypertension is present on manifestation of PRES, the upper limits of autoregulation are however usually not reached.<sup><xref ref-type="bibr" rid="bibr14-0885066610393634">14</xref></sup> Lee et al report a mean peak systolic blood pressure of 187 mm Hg, range 80 to 240 mm Hg, within the day before presentation in 36 patients with PRES.<sup><xref ref-type="bibr" rid="bibr11-0885066610393634">11</xref></sup>
</p>
<p>As PRES is seen within a wide palette of associated conditions, laboratory characteristics may vary considerably, depending on specific pathophysiology and organ involvement. However, laboratory evidence of endothelial injury, as indicated by thrombocytopenia, cell fragmentation with elevated schistocyte counts, and increase in lactate dehydrogenase, seems to be more frequently found across conditions associated with PRES.<sup><xref ref-type="bibr" rid="bibr14-0885066610393634">14</xref><xref ref-type="bibr" rid="bibr15-0885066610393634"/><xref ref-type="bibr" rid="bibr16-0885066610393634"/><xref ref-type="bibr" rid="bibr17-0885066610393634"/>–<xref ref-type="bibr" rid="bibr18-0885066610393634">18</xref></sup> Cerebrospinal fluid findings are usually normal, rarely a mild protein elevation has been reported, however there are few studies available in patients with PRES.<sup><xref ref-type="bibr" rid="bibr11-0885066610393634">11</xref>,<xref ref-type="bibr" rid="bibr19-0885066610393634">19</xref></sup> Lee et al report electroencephalographic findings of slowing in 22 of 28 examined patients, focal sharp waves are less frequently seen (3 of 28 patients), and in 3 of 28 patients electroencephalography was normal.<sup><xref ref-type="bibr" rid="bibr11-0885066610393634">11</xref></sup>
</p>
</sec>
<sec id="section3-0885066610393634">
<title>Imaging Characteristics of PRES</title>
<sec id="section4-0885066610393634">
<title>Lesion Characteristics and Localization</title>
<p>Magnetic resonance imaging (MRI) allows more precise characterization and recognition of PRES than computed tomography (CT) (<xref ref-type="fig" rid="fig1-0885066610393634">Figures 1</xref> and <xref ref-type="fig" rid="fig2-0885066610393634">2</xref>

).<sup><xref ref-type="bibr" rid="bibr3-0885066610393634">3</xref>,<xref ref-type="bibr" rid="bibr9-0885066610393634">9</xref></sup> The lesions in PRES usually show increased signal on T2- (<xref ref-type="fig" rid="fig2-0885066610393634">Figure 2A</xref>) and fluid-attenuated inversion recovery (FLAIR) imaging with increased apparent diffusion coefficient (ADC) values (<xref ref-type="fig" rid="fig2-0885066610393634">Figure 2C</xref>), indicating the presence of vasogenic edema.<sup><xref ref-type="bibr" rid="bibr20-0885066610393634">20</xref><xref ref-type="bibr" rid="bibr21-0885066610393634"/><xref ref-type="bibr" rid="bibr22-0885066610393634"/>–<xref ref-type="bibr" rid="bibr23-0885066610393634">23</xref></sup> On diffusion-weighted imaging (DWI), majority of cases show no change in intensity in the corresponding areas with high T2 signal.<sup><xref ref-type="bibr" rid="bibr9-0885066610393634">9</xref>,<xref ref-type="bibr" rid="bibr24-0885066610393634">24</xref><xref ref-type="bibr" rid="bibr25-0885066610393634"/>–<xref ref-type="bibr" rid="bibr26-0885066610393634">26</xref></sup> A T2 shine-through effect with a slight hyperintensity on DWI is less commonly present (<xref ref-type="fig" rid="fig2-0885066610393634">Figure 2B</xref>).<sup><xref ref-type="bibr" rid="bibr24-0885066610393634">24</xref></sup> Areas of restricted diffusion and hyperintensity on DWI are rarely observed.<sup><xref ref-type="bibr" rid="bibr9-0885066610393634">9</xref>,<xref ref-type="bibr" rid="bibr24-0885066610393634">24</xref></sup> Such lesions with restricted diffusion may show ADC values, which appear normal and are surrounded by regions of vasogenic edema.<sup><xref ref-type="bibr" rid="bibr25-0885066610393634">25</xref></sup> Covarrubias et al describe this phenomenon as “pseudonormalized” ADC, because those changes have been observed by the authors to progress to infarction in 6 patients with PRES.<sup><xref ref-type="bibr" rid="bibr25-0885066610393634">25</xref></sup> Elevated DWI signal combined with decreased ADC usually indicates ischemic areas.<sup><xref ref-type="bibr" rid="bibr26-0885066610393634">26</xref></sup> There are, however, also reports of diffusion restriction with ADC decrease in PRES, with subsequent complete reversibility of imaging changes.<sup><xref ref-type="bibr" rid="bibr24-0885066610393634">24</xref>,<xref ref-type="bibr" rid="bibr27-0885066610393634">27</xref></sup> Single voxel proton MR spectroscopy of the lesions may also help differentiate between infarction and reversible changes in PRES. <italic>N</italic>-acetylaspartate decrease has been reported in PRES lesions, whereas lactate increase, a typical finding in ischemic areas, is usually absent.<sup><xref ref-type="bibr" rid="bibr28-0885066610393634">28</xref><xref ref-type="bibr" rid="bibr29-0885066610393634"/><xref ref-type="bibr" rid="bibr30-0885066610393634"/>–<xref ref-type="bibr" rid="bibr31-0885066610393634">31</xref></sup>
</p>
<fig id="fig1-0885066610393634" position="float">
<label>Figure 1.</label>
<caption>
<p>Computed tomography (CT) of a patient with posterior reversible encephalopathy syndrome showing bilateral occipital hypodensity. Kindly provided by Dr Marios Psychogios and Prof Michael Knauth, Neuroradiology Department, University of Göttingen, Germany.</p>
</caption>
<graphic alternate-form-of="fig1-0885066610393634" xlink:href="10.1177_0885066610393634-fig1.tif"/>
</fig>
<fig id="fig2-0885066610393634" position="float">
<label>Figure 2.</label>
<caption>
<p>Magnetic resonance images (MRI) of a patient with posterior reversible encephalopathy syndrome. Hyperintensive alterations in the occipital and frontal lobes on T2 imaging (A). A slight hyperintensity (T2-shine through effect) on diffusion imaging (B). Increased apparent diffusion coefficient (ADC) values in the corresponding areas indicate vasogenic edema (C). Kindly provided by Dr Marios Psychogios and Prof Michael Knauth, Neuroradiology Department, University of Göttingen, Germany.</p>
</caption>
<graphic alternate-form-of="fig2-0885066610393634" xlink:href="10.1177_0885066610393634-fig2.tif"/>
</fig>
<p>The most common location of white matter abnormalities in PRES is the posterior regions of the cerebral hemispheres, that is, the occipital lobe, the posterior parietal lobe, and the posterior temporal lobe.<sup><xref ref-type="bibr" rid="bibr1-0885066610393634">1</xref>,<xref ref-type="bibr" rid="bibr9-0885066610393634">9</xref>,<xref ref-type="bibr" rid="bibr10-0885066610393634">10</xref>,<xref ref-type="bibr" rid="bibr24-0885066610393634">24</xref></sup> The frontal lobes are also very frequently involved (<xref ref-type="fig" rid="fig2-0885066610393634">Figure 2</xref>).<sup><xref ref-type="bibr" rid="bibr9-0885066610393634">9</xref>,<xref ref-type="bibr" rid="bibr24-0885066610393634">24</xref></sup> Atypical locations such as the cerebellum, the brain stem, the basal ganglia, the deep white matter, or the splenium of the corpus callosum are seen in approximately 10% to 30% of the cases.<sup><xref ref-type="bibr" rid="bibr1-0885066610393634">1</xref>,<xref ref-type="bibr" rid="bibr9-0885066610393634">9</xref>,<xref ref-type="bibr" rid="bibr10-0885066610393634">10</xref>,<xref ref-type="bibr" rid="bibr20-0885066610393634">20</xref>,<xref ref-type="bibr" rid="bibr24-0885066610393634">24</xref></sup> Cortex involvement is frequent (up to approximately 90%) and best recognizable by FLAIR imaging.<sup><xref ref-type="bibr" rid="bibr10-0885066610393634">10</xref></sup> Symmetrical edema is most commonly observed in PRES, asymmetrical or even strictly unilateral manifestations have, however, also been described.<sup><xref ref-type="bibr" rid="bibr9-0885066610393634">9</xref>,<xref ref-type="bibr" rid="bibr24-0885066610393634">24</xref></sup> McKinney et al define 3 levels of severity of PRES distribution in a series of 76 patients, based on FLAIR imaging: mild, moderate, and severe.<sup><xref ref-type="bibr" rid="bibr24-0885066610393634">24</xref></sup> In their analysis, there was no significant correlation between edema severity and the occurrence of restricted diffusion, hemorrhage, contrast enhancement, or maximum systolic or diastolic blood pressure. Bartynski et al, however, did find a correlation. The authors suggest a 5-level grading scale for severity of edema in PRES, in which confluence and extension of the lesions to the ventricular system, as well as involvement of the cortex, the subcortical and deep white matter, and space-occupying effects of the lesions are taken into account.<sup><xref ref-type="bibr" rid="bibr15-0885066610393634">15</xref></sup> Among 25 patients with PRES associated with infection, sepsis, and shock, the authors found a significant correlation between the edema severity grade and blood pressure at the time of neurotoxicity. Interestingly, more severe edema was associated with a “normotensive” blood pressure. In contrast, “severely hypertensive” patients showed lower edema grades.<sup><xref ref-type="bibr" rid="bibr15-0885066610393634">15</xref></sup> Similar findings were reported by Bartynski et al for patients with kidney transplants and PRES.<sup><xref ref-type="bibr" rid="bibr16-0885066610393634">16</xref></sup> The differing results of McKinney et al and Bartynski et al are probably best explained by the use of different edema grading scales with a better sensitivity of the 5-level grading scale.</p>
<p>Although various brain regions may be affected, certain patterns of lesion distribution appear to be more common. Bartynski et al<sup><xref ref-type="bibr" rid="bibr9-0885066610393634">9</xref></sup> have made an attempt to classify PRES lesion distribution and found 3 major patterns analyzing a large series of 136 patients with PRES: the first is a holohemispheric watershed pattern consisting of a linear distribution of edema spanning the frontal, parietal, and occipital lobes, with lesser involvement of the temporal lobes. This linear distribution of the lesions seems to be consistent with the anastomotic border zone between medial (posterior cerebral artery [PCA]; anterior cerebral artery [ACA]) and lateral (medial cerebral artery [MCA]) vessel branches. The severity of manifestation ranges from extensive to mild, with a “string of pearls” appearance of nonconfluent white matter lesions. The other 2 major patterns are a superior frontal sulcus pattern with predominant involvement of the mid-to-posterior aspect of the superior frontal sulcus with varying degrees of parietooccipital abnormality and a dominant parietooccipital pattern with involvement of the parietal and occipital lobes and variable temporal lobe manifestations. Each of those patterns was observed in approximately one fourth of the patients. The remaining patients showed incomplete or asymmetrical expression of the described lesion distribution patterns, partially with strictly unilateral abnormality. The imaging distribution patterns did not correlate with clinical features of the syndrome in that study. Analyzing lesion distribution in 24 patients with PRES, another work group found a significantly higher number of lesions and a trend for increased basal ganglia involvement in patients with PRES in the setting of preeclampsia−eclampsia, as compared to other causes.<sup><xref ref-type="bibr" rid="bibr32-0885066610393634">32</xref></sup>
</p>
<p>Contrast enhancement on post-gadolinium MRI, although rarely addressed in literature, is present in up to 38% of patients with PRES.<sup><xref ref-type="bibr" rid="bibr24-0885066610393634">24</xref></sup> A gyriform pattern of distribution has most commonly been described.<sup><xref ref-type="bibr" rid="bibr3-0885066610393634">3</xref>,<xref ref-type="bibr" rid="bibr21-0885066610393634">21</xref>,<xref ref-type="bibr" rid="bibr33-0885066610393634">33</xref>,<xref ref-type="bibr" rid="bibr34-0885066610393634">34</xref></sup> Contrast enhancement possibly results from endothelial injury and subsequent blood–brain barrier breakdown.<sup><xref ref-type="bibr" rid="bibr35-0885066610393634">35</xref></sup> Because of the different etiology of endothelial damage, for example, by immunosuppressive drugs such as cyclosporine after solid organ transplantation, or hypoperfusion in eclampsia, there may be discrepancies in the extent of contrast enhancement dependent on the underlying cause of PRES.<sup><xref ref-type="bibr" rid="bibr24-0885066610393634">24</xref></sup>
</p>
</sec>
<sec id="section5-0885066610393634">
<title>Cerebral Hemorrhage in PRES</title>
<p>Cerebral hemorrhage is known to occur in PRES, and case series report it in 5% to 17% of patients.<sup><xref ref-type="bibr" rid="bibr11-0885066610393634">11</xref>,<xref ref-type="bibr" rid="bibr24-0885066610393634">24</xref>,<xref ref-type="bibr" rid="bibr25-0885066610393634">25</xref>,<xref ref-type="bibr" rid="bibr36-0885066610393634">36</xref>,<xref ref-type="bibr" rid="bibr37-0885066610393634">37</xref></sup> In a recently published study on 151 patients with PRES, Hefzy et al report 3 different types of hemorrhage: minute (punctual) hemorrhage, sulcal (subarachnoid) hemorrhage, and focal hematoma.<sup><xref ref-type="bibr" rid="bibr36-0885066610393634">36</xref></sup> In this largest analysis focusing on hemorrhage in PRES, a borderline significant statistical trend (<italic>P</italic> = .07) for an association between the occurrence of hemorrhage and underlying etiology of PRES was found. When looking at allogenic bone marrow transplantation (allo-BMT; hemorrhage rate of 46.6%) and solid organ transplantation (hemorrhage rate of 11.7%), the authors identified a statistically significant difference. Focal hemorrhage rates were also significantly greater in allo-BMT patients. Patients with therapeutic anticoagulation or those taking aspirin were significantly more likely to develop PRES-associated hemorrhage, in contrast to patients with intrinsic coagulopathy. There was no association between hemorrhage occurrence and blood pressure. Even excluding the subset of allo-BMT patients, severe hypertension was less frequently associated with hemorrhage.<sup><xref ref-type="bibr" rid="bibr36-0885066610393634">36</xref></sup> This finding may indicate that hemorrhage in PRES is not directly caused by severe hypertension but rather a consequence of initial hypoperfusion and subsequent reperfusion injury.</p>
</sec>
<sec id="section6-0885066610393634">
<title>Vascular and Cerebral Perfusion Imaging</title>
<p>The state of cerebral perfusion in PRES is still a subject of controversy because of contradictory findings reported in different studies. Animal studies suggest that experimentally induced hypertension above the autoregulatory limit leads to breakdown of the blood–brain barrier, hyperperfusion, and leakage of fluid into the brain, with subsequent vasogenic edema.<sup><xref ref-type="bibr" rid="bibr38-0885066610393634">38</xref></sup> The evidence of hyperperfusion in the clinical setting of PRES is, however, not convincing. Single reports of hyperperfusion in PRES detected either by single-photon emission computed tomography (SPECT)<sup><xref ref-type="bibr" rid="bibr2-0885066610393634">2</xref>,<xref ref-type="bibr" rid="bibr39-0885066610393634">39</xref></sup> or by MR-perfusion imaging<sup><xref ref-type="bibr" rid="bibr40-0885066610393634">40</xref></sup> have been published. There is, however, controversy on the interpretation of those findings.<sup><xref ref-type="bibr" rid="bibr14-0885066610393634">14</xref>,<xref ref-type="bibr" rid="bibr40-0885066610393634">40</xref></sup>
</p>
<p>The majority of studies on cerebral perfusion imaging in PRES reports hypoperfusion in the affected areas with vasogenic edema.<sup><xref ref-type="bibr" rid="bibr15-0885066610393634">15</xref>,<xref ref-type="bibr" rid="bibr28-0885066610393634">28</xref>,<xref ref-type="bibr" rid="bibr41-0885066610393634">41</xref><xref ref-type="bibr" rid="bibr42-0885066610393634"/>–<xref ref-type="bibr" rid="bibr43-0885066610393634">43</xref></sup> In studies using MR-perfusion imaging, a reduction of relative cerebral blood volume (rCBV) in the affected areas of the brain has been reported.<sup><xref ref-type="bibr" rid="bibr41-0885066610393634">41</xref>,<xref ref-type="bibr" rid="bibr43-0885066610393634">43</xref></sup> Reductions in rCBV measured in edematous areas range from one third up to two thirds of reference normal cortical rCBV.<sup><xref ref-type="bibr" rid="bibr41-0885066610393634">41</xref>,<xref ref-type="bibr" rid="bibr43-0885066610393634">43</xref>,<xref ref-type="bibr" rid="bibr44-0885066610393634">44</xref></sup> In a large case series of women with eclampsia, brain perfusion assessed by SPECT has also demonstrated perfusion deficits in the predominantly affected watershed areas, in which PRES lesions occur.<sup><xref ref-type="bibr" rid="bibr45-0885066610393634">45</xref></sup> Hypoperfusion has also been reported using CT-perfusion imaging in a patient with PRES.<sup><xref ref-type="bibr" rid="bibr46-0885066610393634">46</xref></sup>
</p>
<p>These findings are usually coupled with vessel irregularities and vasospasm shown on vascular imaging.<sup><xref ref-type="bibr" rid="bibr15-0885066610393634">15</xref>,<xref ref-type="bibr" rid="bibr28-0885066610393634">28</xref>,<xref ref-type="bibr" rid="bibr41-0885066610393634">41</xref>,<xref ref-type="bibr" rid="bibr42-0885066610393634">42</xref></sup> Catheter angiography<sup><xref ref-type="bibr" rid="bibr41-0885066610393634">41</xref>,<xref ref-type="bibr" rid="bibr47-0885066610393634">47</xref><xref ref-type="bibr" rid="bibr48-0885066610393634"/><xref ref-type="bibr" rid="bibr49-0885066610393634"/><xref ref-type="bibr" rid="bibr50-0885066610393634"/>–<xref ref-type="bibr" rid="bibr51-0885066610393634">51</xref></sup> and MR angiography studies<sup><xref ref-type="bibr" rid="bibr15-0885066610393634">15</xref>,<xref ref-type="bibr" rid="bibr28-0885066610393634">28</xref>,<xref ref-type="bibr" rid="bibr41-0885066610393634">41</xref>,<xref ref-type="bibr" rid="bibr42-0885066610393634">42</xref>,<xref ref-type="bibr" rid="bibr52-0885066610393634">52</xref><xref ref-type="bibr" rid="bibr53-0885066610393634"/>–<xref ref-type="bibr" rid="bibr54-0885066610393634">54</xref></sup> in patients with PRES have demonstrated vascular abnormalities as focal vasoconstriction, focal vasodilation, “string-of-bead,” or “string-of-sausages” appearance. Follow-up MR angiography usually demonstrates reversal of vasculopathy.<sup><xref ref-type="bibr" rid="bibr41-0885066610393634">41</xref></sup>
</p>
</sec>
</sec>
<sec id="section7-0885066610393634">
<title>Conditions Associated With PRES</title>
<p>PRES has been associated with a variety of conditions and predisposing factors, which are summarized in <xref ref-type="table" rid="table1-0885066610393634">Table 1</xref>
.</p>
<table-wrap id="table1-0885066610393634" position="float">
<label>Table 1.</label>
<caption>
<p>Conditions and Predisposing Factors Associated With PRES<sup><xref ref-type="table-fn" rid="table-fn2-0885066610393634">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0885066610393634" xlink:href="10.1177_0885066610393634-table1.tif"/>
<table>
<tbody>
<tr>
<td align="left">Frequent associations</td>
</tr>
<tr>
<td align="left"> Hypertension</td>
</tr>
<tr>
<td align="left"> preeclampsia–eclampsia</td>
</tr>
<tr>
<td align="left"> Posttransplantation/immune suppression</td>
</tr>
<tr>
<td align="left">  Cyclosporine, tacrolimus</td>
</tr>
<tr>
<td align="left"> Cytotoxic treatment</td>
</tr>
<tr>
<td align="left"> Autoimmune diseases</td>
</tr>
<tr>
<td align="left">  Systemic lupus erythematodes, Wegener granulomatosis, scleroderma, polyarteriitis nodosa, psoriasis, Graves disease, rheumatoid factor positive arthropathy</td>
</tr>
<tr>
<td align="left"> Infection/sepsis</td>
</tr>
<tr>
<td align="left">Rare associations</td>
</tr>
<tr>
<td align="left"> Hypomagnesemia</td>
</tr>
<tr>
<td align="left"> Hypercalcemia</td>
</tr>
<tr>
<td align="left"> Hypercholesterolemia</td>
</tr>
<tr>
<td align="left"> Intravenous immunoglobulin</td>
</tr>
<tr>
<td align="left"> Linezolid treatment</td>
</tr>
<tr>
<td align="left"> Guillain-Barre syndrome</td>
</tr>
<tr>
<td align="left"> Ephedra overdose</td>
</tr>
<tr>
<td align="left"> Triple H therapy</td>
</tr>
<tr>
<td align="left"> Tumor lysis syndrome</td>
</tr>
<tr>
<td align="left"> Hydrogen peroxide</td>
</tr>
<tr>
<td align="left"> Dimethyl sulfoxide stem cells</td>
</tr>
<tr>
<td align="left"> Contrast media exposure</td>
</tr>
<tr>
<td align="left"> Corticosteroid treatment</td>
</tr>
<tr>
<td align="left"> Lysergic acid diethylamide</td>
</tr>
<tr>
<td align="left"> Scorpion poison</td>
</tr>
<tr>
<td align="left"> <italic>Averrhoa carambola</italic> ingestion</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0885066610393634">
<p>Abbreviation: PRES, posterior reversible encephalopathy syndrome.</p>
</fn>
<fn id="table-fn2-0885066610393634">
<p>
<sup>a</sup> For references see text.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Moderate-to-severe hypertension, commonly present in PRES, is reported in approximately 75% of cases.<sup><xref ref-type="bibr" rid="bibr14-0885066610393634">14</xref></sup> Hypertension has been recognized as a major factor in the setting of PRES, which has contributed to the implementation of the earlier term “hypertensive encephalopathy.” Various patterns of lesion distribution have been associated with HTE,<sup><xref ref-type="bibr" rid="bibr3-0885066610393634">3</xref>,<xref ref-type="bibr" rid="bibr4-0885066610393634">4</xref>,<xref ref-type="bibr" rid="bibr34-0885066610393634">34</xref>,<xref ref-type="bibr" rid="bibr55-0885066610393634">55</xref><xref ref-type="bibr" rid="bibr56-0885066610393634"/><xref ref-type="bibr" rid="bibr57-0885066610393634"/><xref ref-type="bibr" rid="bibr58-0885066610393634"/><xref ref-type="bibr" rid="bibr59-0885066610393634"/>–<xref ref-type="bibr" rid="bibr60-0885066610393634">60</xref></sup> including hemispheric distribution of lesions or brain stem and cerebellar edema, in 1 case resulting in obstructive hydrocephalus.<sup><xref ref-type="bibr" rid="bibr58-0885066610393634">58</xref></sup> The differentiation between deep white matter lesions and chronic changes due to hypertension (lacunar disease) may be difficult.</p>
<p>The association of preeclampsia−eclampsia and PRES is well documented.<sup><xref ref-type="bibr" rid="bibr32-0885066610393634">32</xref>,<xref ref-type="bibr" rid="bibr47-0885066610393634">47</xref>,<xref ref-type="bibr" rid="bibr61-0885066610393634">61</xref><xref ref-type="bibr" rid="bibr62-0885066610393634"/><xref ref-type="bibr" rid="bibr63-0885066610393634"/><xref ref-type="bibr" rid="bibr64-0885066610393634"/><xref ref-type="bibr" rid="bibr65-0885066610393634"/><xref ref-type="bibr" rid="bibr66-0885066610393634"/><xref ref-type="bibr" rid="bibr67-0885066610393634"/><xref ref-type="bibr" rid="bibr68-0885066610393634"/><xref ref-type="bibr" rid="bibr69-0885066610393634"/><xref ref-type="bibr" rid="bibr70-0885066610393634"/><xref ref-type="bibr" rid="bibr71-0885066610393634"/><xref ref-type="bibr" rid="bibr72-0885066610393634"/>–<xref ref-type="bibr" rid="bibr73-0885066610393634">73</xref></sup> Preeclampsia is responsible for the world’s largest maternal death rates of approximately 60 000 per year.<sup><xref ref-type="bibr" rid="bibr74-0885066610393634">74</xref></sup> Acute cerebral complications, such as eclampsia, cerebral edema, and intracerebral hemorrhage, account for the majority of fatalities.<sup><xref ref-type="bibr" rid="bibr75-0885066610393634">75</xref>,<xref ref-type="bibr" rid="bibr76-0885066610393634">76</xref></sup> PRES is hypothesized to be the primary injury in eclampsia. Following the general trend, hypertension is absent in approximately one fourth of the women who develop PRES.<sup><xref ref-type="bibr" rid="bibr77-0885066610393634">77</xref></sup> The placenta is thought to be the primary cause of toxemia, and placenta removal is considered curative.<sup><xref ref-type="bibr" rid="bibr78-0885066610393634">78</xref></sup> Delayed eclampsia, with PRES within several weeks after delivery may also occur.<sup><xref ref-type="bibr" rid="bibr48-0885066610393634">48</xref>,<xref ref-type="bibr" rid="bibr50-0885066610393634">50</xref></sup> In a recently reported case of delayed postpartum PRES occurrence, retained placental fragments were suggested as the underlying cause.<sup><xref ref-type="bibr" rid="bibr79-0885066610393634">79</xref></sup> No specific lesion distribution patterns have been associated with this condition, however, a trend toward more frequent involvement of the basal ganglia and a significantly higher number of involved brain regions have been observed in PRES in the setting of preeclampsia–eclampsia, as compared to other underlying conditions.<sup><xref ref-type="bibr" rid="bibr32-0885066610393634">32</xref></sup>
</p>
<p>PRES has been frequently described in the setting of allo-BMT or stem cell transplantation,<sup><xref ref-type="bibr" rid="bibr2-0885066610393634">2</xref>,<xref ref-type="bibr" rid="bibr18-0885066610393634">18</xref>,<xref ref-type="bibr" rid="bibr80-0885066610393634">80</xref><xref ref-type="bibr" rid="bibr81-0885066610393634"/><xref ref-type="bibr" rid="bibr82-0885066610393634"/><xref ref-type="bibr" rid="bibr83-0885066610393634"/>–<xref ref-type="bibr" rid="bibr84-0885066610393634">84</xref></sup> as well as after solid organ transplantation,<sup><xref ref-type="bibr" rid="bibr85-0885066610393634">85</xref><xref ref-type="bibr" rid="bibr86-0885066610393634"/><xref ref-type="bibr" rid="bibr87-0885066610393634"/><xref ref-type="bibr" rid="bibr88-0885066610393634"/><xref ref-type="bibr" rid="bibr89-0885066610393634"/><xref ref-type="bibr" rid="bibr90-0885066610393634"/><xref ref-type="bibr" rid="bibr91-0885066610393634"/><xref ref-type="bibr" rid="bibr92-0885066610393634"/><xref ref-type="bibr" rid="bibr93-0885066610393634"/><xref ref-type="bibr" rid="bibr94-0885066610393634"/><xref ref-type="bibr" rid="bibr95-0885066610393634"/><xref ref-type="bibr" rid="bibr96-0885066610393634"/>–<xref ref-type="bibr" rid="bibr97-0885066610393634">97</xref></sup> mostly in connection with cyclosporine or tacrolimus neurotoxicity. PRES occurs most commonly in the first month after allo-BMT, the remaining cases usually within 1 year after transplantation.<sup><xref ref-type="bibr" rid="bibr80-0885066610393634">80</xref>,<xref ref-type="bibr" rid="bibr83-0885066610393634">83</xref>,<xref ref-type="bibr" rid="bibr89-0885066610393634">89</xref>,<xref ref-type="bibr" rid="bibr98-0885066610393634">98</xref></sup> The incidence of PRES seems to vary with different preconditioning regimens and comprises approximately 7% to 9% using myeloablative marrow preconditioning and cyclosporine immune suppression.<sup><xref ref-type="bibr" rid="bibr80-0885066610393634">80</xref>,<xref ref-type="bibr" rid="bibr83-0885066610393634">83</xref>,<xref ref-type="bibr" rid="bibr98-0885066610393634">98</xref></sup> Even higher incidences (approximately 16%) have been reported using higher dose myeloablative regimens, in contrast to a PRES incidence of only 3% when nonmyeloablative preconditioning was used.<sup><xref ref-type="bibr" rid="bibr81-0885066610393634">81</xref>,<xref ref-type="bibr" rid="bibr98-0885066610393634">98</xref></sup> As higher incidence of graft versus host disease (GVHD) has been identified in patients developing PRES, GVHD effects have been suggested to play a role in the pathogenesis of PRES.<sup><xref ref-type="bibr" rid="bibr84-0885066610393634">84</xref>,<xref ref-type="bibr" rid="bibr99-0885066610393634">99</xref><xref ref-type="bibr" rid="bibr100-0885066610393634"/>–<xref ref-type="bibr" rid="bibr101-0885066610393634">101</xref></sup>
</p>
<p>In solid organ transplantation, PRES incidence has been reported to vary between 0.4% and 6%.<sup><xref ref-type="bibr" rid="bibr16-0885066610393634">16</xref>,<xref ref-type="bibr" rid="bibr95-0885066610393634">95</xref>,<xref ref-type="bibr" rid="bibr102-0885066610393634">102</xref></sup> PRES seems to occur earlier in the course after liver transplantation—in most cases within 2 months—and markedly later after kidney transplantation.<sup><xref ref-type="bibr" rid="bibr16-0885066610393634">16</xref>,<xref ref-type="bibr" rid="bibr102-0885066610393634">102</xref></sup> Systemic hypertension is more often noted after kidney transplantation compared to liver, lung, or heart transplantation, and hypertensive patients tend to develop less brain edema than normotensive patients with PRES.<sup><xref ref-type="bibr" rid="bibr14-0885066610393634">14</xref>,<xref ref-type="bibr" rid="bibr16-0885066610393634">16</xref>,<xref ref-type="bibr" rid="bibr94-0885066610393634">94</xref>,<xref ref-type="bibr" rid="bibr102-0885066610393634">102</xref>,<xref ref-type="bibr" rid="bibr103-0885066610393634">103</xref></sup> Transplant rejection and infection have been reported to often accompany PRES after solid organ transplantation.<sup><xref ref-type="bibr" rid="bibr16-0885066610393634">16</xref></sup>
</p>
<p>High-dose multidrug cytotoxic chemotherapy has also been associated with PRES, especially in children with leukemia.<sup><xref ref-type="bibr" rid="bibr104-0885066610393634">104</xref>,<xref ref-type="bibr" rid="bibr105-0885066610393634"/><xref ref-type="bibr" rid="bibr106-0885066610393634"/>–<xref ref-type="bibr" rid="bibr107-0885066610393634">107</xref></sup> Additionally, several chemotherapeutic drugs have been reported in connection with PRES: cytarabine,<sup><xref ref-type="bibr" rid="bibr108-0885066610393634">108</xref>,<xref ref-type="bibr" rid="bibr109-0885066610393634">109</xref></sup> cisplatin,<sup><xref ref-type="bibr" rid="bibr110-0885066610393634">110</xref></sup> gemcitabine,<sup><xref ref-type="bibr" rid="bibr30-0885066610393634">30</xref></sup> tiazofurin,<sup><xref ref-type="bibr" rid="bibr111-0885066610393634">111</xref></sup> and bevacizumab.<sup><xref ref-type="bibr" rid="bibr112-0885066610393634">112</xref>,<xref ref-type="bibr" rid="bibr113-0885066610393634">113</xref></sup>
</p>
<p>In recent years, reports of PRES in patients with connective tissue diseases, the majority of them with systemic lupus erythematosus (SLE) and also Wegener granulomatosis, polyarteriitis nodosa, scleroderma, psoriasis, Graves disease, and rheumatoid factor positive arthropathy have accumulated.<sup><xref ref-type="bibr" rid="bibr1-0885066610393634">1</xref>,<xref ref-type="bibr" rid="bibr3-0885066610393634">3</xref>,<xref ref-type="bibr" rid="bibr6-0885066610393634">6</xref>,<xref ref-type="bibr" rid="bibr15-0885066610393634">15</xref>,<xref ref-type="bibr" rid="bibr53-0885066610393634">53</xref>,<xref ref-type="bibr" rid="bibr114-0885066610393634">114</xref>,<xref ref-type="bibr" rid="bibr115-0885066610393634"/><xref ref-type="bibr" rid="bibr116-0885066610393634"/><xref ref-type="bibr" rid="bibr117-0885066610393634"/><xref ref-type="bibr" rid="bibr118-0885066610393634"/><xref ref-type="bibr" rid="bibr119-0885066610393634"/><xref ref-type="bibr" rid="bibr120-0885066610393634"/><xref ref-type="bibr" rid="bibr121-0885066610393634"/><xref ref-type="bibr" rid="bibr122-0885066610393634"/><xref ref-type="bibr" rid="bibr123-0885066610393634"/><xref ref-type="bibr" rid="bibr124-0885066610393634"/><xref ref-type="bibr" rid="bibr125-0885066610393634"/><xref ref-type="bibr" rid="bibr126-0885066610393634"/><xref ref-type="bibr" rid="bibr127-0885066610393634"/><xref ref-type="bibr" rid="bibr128-0885066610393634"/><xref ref-type="bibr" rid="bibr129-0885066610393634"/><xref ref-type="bibr" rid="bibr130-0885066610393634"/><xref ref-type="bibr" rid="bibr131-0885066610393634"/><xref ref-type="bibr" rid="bibr132-0885066610393634"/>–<xref ref-type="bibr" rid="bibr133-0885066610393634">133</xref></sup> The particular role of the underlying connective tissue disease in the pathogenesis of PRES is not clear in those cases, because comorbidity like hypertension, renal involvement with renal insufficiency, infection, or recent immunosuppressive treatment with corticosteroids, cyclophosphamide, cyclosporine, mycophenolate mofetil, rituximab, and azathioprine, all factors separately associated with PRES, were present in most patients.<sup><xref ref-type="bibr" rid="bibr133-0885066610393634">133</xref></sup> Interestingly, withdrawal of putatively causative immunosuppressive drugs on one hand, and administration of high-dose corticosteroids or adjunctive immunosuppressive drugs, including cyclophosphamide or mycophenolate mofetil on the other hand have been reported to lead to successful treatment of PRES.<sup><xref ref-type="bibr" rid="bibr133-0885066610393634">133</xref>,<xref ref-type="bibr" rid="bibr134-0885066610393634">134</xref></sup>
</p>
<p>A recent study of 106 patients identified infection and sepsis as an important, though not yet recognized cause of PRES, particularly in relation to infection with gram-positive organisms.<sup><xref ref-type="bibr" rid="bibr15-0885066610393634">15</xref></sup> Infection and sepsis have been suggested to be responsible for one fourth of the cases with PRES in this study.<sup><xref ref-type="bibr" rid="bibr15-0885066610393634">15</xref></sup> This observation has, however, yet to be confirmed in other studies.</p>
<p>Rarely or anecdotally reported associations with PRES include hypomagnesemia, hypercalcemia, hypercholesterolemia, acute pancreatitis, intravenous immunoglobulin, linezolid treatment, Guillain-Barré syndrome, Ephedra overdose, triple H therapy, tumor lysis syndrome, hydrogen peroxide, contrast media exposure, corticosteroid treatment, influenza A infection, lysergic acid amide, and scorpion poison.<sup><xref ref-type="bibr" rid="bibr13-0885066610393634">13</xref>,<xref ref-type="bibr" rid="bibr19-0885066610393634">19</xref>,<xref ref-type="bibr" rid="bibr135-0885066610393634">135</xref>,<xref ref-type="bibr" rid="bibr136-0885066610393634"/><xref ref-type="bibr" rid="bibr137-0885066610393634"/><xref ref-type="bibr" rid="bibr138-0885066610393634"/><xref ref-type="bibr" rid="bibr139-0885066610393634"/><xref ref-type="bibr" rid="bibr140-0885066610393634"/><xref ref-type="bibr" rid="bibr141-0885066610393634"/><xref ref-type="bibr" rid="bibr142-0885066610393634"/><xref ref-type="bibr" rid="bibr143-0885066610393634"/><xref ref-type="bibr" rid="bibr144-0885066610393634"/><xref ref-type="bibr" rid="bibr145-0885066610393634"/><xref ref-type="bibr" rid="bibr146-0885066610393634"/><xref ref-type="bibr" rid="bibr147-0885066610393634"/><xref ref-type="bibr" rid="bibr148-0885066610393634"/><xref ref-type="bibr" rid="bibr149-0885066610393634"/><xref ref-type="bibr" rid="bibr150-0885066610393634"/>–<xref ref-type="bibr" rid="bibr151-0885066610393634">151</xref></sup>
</p>
</sec>
<sec id="section8-0885066610393634">
<title>Pathophysiology of PRES</title>
<p>The mechanism of PRES is still poorly understood and controversial. There are 2 commonly cited opposing hypotheses on the pathogenesis of PRES. The older hypothesis states that hypertension leads to autoregulatory vasoconstriction and hypoperfusion with resulting ischemia and cerebral edema.<sup><xref ref-type="bibr" rid="bibr152-0885066610393634">152</xref></sup> This idea was supported by findings of edema in the posterior cerebral regions combined with vasospasm on vascular imaging in patients with eclampsia and hypertension.<sup><xref ref-type="bibr" rid="bibr48-0885066610393634">48</xref>,<xref ref-type="bibr" rid="bibr153-0885066610393634">153</xref></sup> The newer hypothesis suggests that severe hypertension exceeds the autoregulatory limits of the cerebral vasculature and leads to breakthrough of the blood–brain barrier, fluid leakage, and vasogenic edema.<sup><xref ref-type="bibr" rid="bibr3-0885066610393634">3</xref></sup> This more intuitive explanation has become popular in recent years, mainly because of the frequently reported benefit of emergent hypertension treatment with subsequent recovery of symptoms and alterations in imaging.<sup><xref ref-type="bibr" rid="bibr13-0885066610393634">13</xref>,<xref ref-type="bibr" rid="bibr154-0885066610393634">154</xref></sup> Moreover, animal studies investigating the cerebral squealae of severe hypertension have demonstrated breakthrough of the blood–brain barrier, hyperperfusion, and vasogenic edema when the upper limits of autoregulation are exceeded.<sup><xref ref-type="bibr" rid="bibr38-0885066610393634">38</xref>,<xref ref-type="bibr" rid="bibr155-0885066610393634">155</xref></sup>
</p>
<p>However, the role of hypertension in PRES has not been sufficiently elucidated yet and continues to be the subject of controversy.<sup><xref ref-type="bibr" rid="bibr152-0885066610393634">152</xref></sup> In humans, the upper limits of autoregulation are usually reached at a mean arterial pressure (MAP) of 150 to 160 mm Hg.<sup><xref ref-type="bibr" rid="bibr155-0885066610393634">155</xref>,<xref ref-type="bibr" rid="bibr156-0885066610393634">156</xref></sup> Due to the rich sympathetic innervation of cerebral vessels, sympathetic stimulation leads to increase of the upper limit of autoregulation by up to 30 mm Hg MAP.<sup><xref ref-type="bibr" rid="bibr152-0885066610393634">152</xref></sup> Those limits are also increased in patients with chronic hypertension.<sup><xref ref-type="bibr" rid="bibr152-0885066610393634">152</xref></sup> Given the considerable prevalence of moderate-to-severe hypertension in the setting of PRES (up to 75% of patients), it should be noted that observed blood pressure levels, although in some reported cases elevated quite severely,<sup><xref ref-type="bibr" rid="bibr56-0885066610393634">56</xref>,<xref ref-type="bibr" rid="bibr157-0885066610393634">157</xref></sup> in the majority of cases it does not reach the upper limits of autoregulation.<sup><xref ref-type="bibr" rid="bibr1-0885066610393634">1</xref>,<xref ref-type="bibr" rid="bibr9-0885066610393634">9</xref>,<xref ref-type="bibr" rid="bibr41-0885066610393634">41</xref>,98a,<xref ref-type="bibr" rid="bibr122-0885066610393634">122</xref></sup> Furthermore, circumstances leading to increased levels of autoregulation are a common finding in PRES, for example, chronic hypertension, or increased sympathetic stimulation, as reported in patients treated with cyclosporine.<sup><xref ref-type="bibr" rid="bibr158-0885066610393634">158</xref>,<xref ref-type="bibr" rid="bibr159-0885066610393634">159</xref></sup> Moreover, PRES is frequently seen without hypertension, as reported in patients with eclampsia, after allo-BMT or solid organ transplantation.<sup><xref ref-type="bibr" rid="bibr9-0885066610393634">9</xref>,<xref ref-type="bibr" rid="bibr18-0885066610393634">18</xref>,<xref ref-type="bibr" rid="bibr77-0885066610393634">77</xref></sup> In this subset of patients, however, “relative hypertension” may play a role. Women with eclampsia having borderline hypertensive blood pressure values (systolic pressure of less than 140 mm Hg) are often young primigravidas whose blood pressures have risen from markedly low baseline levels.<sup><xref ref-type="bibr" rid="bibr74-0885066610393634">74</xref></sup> The importance of this mechanism for the pathogenesis of PRES is yet still unclear. Some recent findings show that the severity of cerebral edema is inversely correlated to the blood pressure level in patients with PRES.<sup><xref ref-type="bibr" rid="bibr15-0885066610393634">15</xref>,<xref ref-type="bibr" rid="bibr16-0885066610393634">16</xref>,<xref ref-type="bibr" rid="bibr41-0885066610393634">41</xref></sup> Those observations have led to the speculation that increased blood pressure may represent a secondary event in the mechanism of disease, not causing edema by fluid leakage, but rather appearing as a reaction to hypoperfusion and ischemia, thus supportive for the older hypothesis of pathogenesis.<sup><xref ref-type="bibr" rid="bibr152-0885066610393634">152</xref></sup> Although animal studies underpin the hypothesis of breakthrough of the blood–brain barrier by increased MAP,<sup><xref ref-type="bibr" rid="bibr38-0885066610393634">38</xref></sup> those observations have been made on otherwise healthy animals, in contrast to the usually very complex systemic conditions associated with PRES in humans. Apart from hypertension, other common findings across underlying conditions may give further clues regarding the pathophysiology of PRES.</p>
<p>Looking at the major conditions, in the setting of which PRES commonly occurs, namely transplantation, autoimmune disease, preeclampsia−eclampsia, cancer chemotherapy, infection, and sepsis, endothelial injury to a certain extent seems to be almost uniformly present. In allo-BMT, the combination of preconditioning regimens and following GVHD leads to release of proinflammatory cytokines and endothelial activation or injury.<sup><xref ref-type="bibr" rid="bibr98-0885066610393634">98</xref>,<xref ref-type="bibr" rid="bibr99-0885066610393634">99</xref>,<xref ref-type="bibr" rid="bibr160-0885066610393634">160</xref></sup> In solid organ transplantation, graft rejection related to a T-cell response is additionally associated with the development of antiendothelial antibodies, primarily against the allogenic transplant.<sup><xref ref-type="bibr" rid="bibr161-0885066610393634">161</xref></sup> On the other hand, immunologically active cells within a liver transplant may contribute to a GVHD similar mechanism of endothelial damage.<sup><xref ref-type="bibr" rid="bibr98-0885066610393634">98</xref></sup> Autoimmune diseases as SLE and Wegener granulomatosis are characterized by vasculitis.<sup><xref ref-type="bibr" rid="bibr162-0885066610393634">162</xref></sup> In toxemia of pregnancy, a placenta−maternal immune reaction is considered the underlying cause of cytokine release, endothelial activation, and injury.<sup><xref ref-type="bibr" rid="bibr78-0885066610393634">78</xref></sup> Furthermore, antiendothelial antibodies are more frequently found in women with eclampsia, as compared to healthy pregnancies (50% vs 16%).<sup><xref ref-type="bibr" rid="bibr78-0885066610393634">78</xref></sup> In cancer, immunologic reaction to cancer, or direct damage of the endothelium by chemotherapeutic drugs are possible mechanisms of endothelial injury.<sup><xref ref-type="bibr" rid="bibr98-0885066610393634">98</xref>,<xref ref-type="bibr" rid="bibr152-0885066610393634">152</xref></sup> Endothelial activation in infection, triggered by bacterial endotoxins, and endothelial injury in sepsis represent an important part of the primary infection response and secondary septic response.<sup><xref ref-type="bibr" rid="bibr163-0885066610393634">163</xref></sup> Laboratory markers of endothelial injury, namely thrombocytopenia, cell fragmentation (schistocytes), and elevated lactate dehydrogenase, are commonly found across those conditions.<sup><xref ref-type="bibr" rid="bibr14-0885066610393634">14</xref></sup> Considering the important role of the endothelium in cerebral autoregulation and its vasodilator influence,<sup><xref ref-type="bibr" rid="bibr164-0885066610393634">164</xref></sup> endothelial injury in PRES-associated conditions may lead to vascular instability and vasoconstriction, with subsequent hypoperfusion.<sup><xref ref-type="bibr" rid="bibr152-0885066610393634">152</xref>,<xref ref-type="bibr" rid="bibr164-0885066610393634">164</xref></sup> Cerebral hypoperfusion of the regions showing abnormalities on imaging in PRES, accompanied by evidence of vasculopathy and vasoconstriction on vascular imaging, has been indeed better documented, <sup><xref ref-type="bibr" rid="bibr15-0885066610393634">15</xref>,<xref ref-type="bibr" rid="bibr28-0885066610393634">28</xref>,<xref ref-type="bibr" rid="bibr41-0885066610393634">41</xref><xref ref-type="bibr" rid="bibr42-0885066610393634"/><xref ref-type="bibr" rid="bibr43-0885066610393634"/><xref ref-type="bibr" rid="bibr44-0885066610393634"/><xref ref-type="bibr" rid="bibr45-0885066610393634"/><xref ref-type="bibr" rid="bibr46-0885066610393634"/><xref ref-type="bibr" rid="bibr47-0885066610393634"/><xref ref-type="bibr" rid="bibr48-0885066610393634"/><xref ref-type="bibr" rid="bibr49-0885066610393634"/><xref ref-type="bibr" rid="bibr50-0885066610393634"/><xref ref-type="bibr" rid="bibr51-0885066610393634"/><xref ref-type="bibr" rid="bibr52-0885066610393634"/><xref ref-type="bibr" rid="bibr53-0885066610393634"/>–<xref ref-type="bibr" rid="bibr54-0885066610393634">54</xref></sup> as compared to the sporadic reports of hyperperfusion.<sup><xref ref-type="bibr" rid="bibr2-0885066610393634">2</xref>,<xref ref-type="bibr" rid="bibr39-0885066610393634">39</xref>,<xref ref-type="bibr" rid="bibr40-0885066610393634">40</xref></sup> Therefore, the available evidence seems to be in better unison with the older hypothesis on the pathogenesis of PRES, which considers hypoperfusion central. In this context, the occurrence of edema patterns in the watershed areas of cerebral circulation is also better explained.</p>
<p>Speculations have been made in order to explain the predominant involvement of the posterior parts of the brain in PRES. One explanation has been proposed by Schwartz et al.<sup><xref ref-type="bibr" rid="bibr3-0885066610393634">3</xref></sup> The authors mention the evidence of a protective effect of sympathetic innervation of the cerebral vasculature against marked increases of blood pressure.<sup><xref ref-type="bibr" rid="bibr165-0885066610393634">165</xref></sup> Based on a histofluorescence study by Edvinsson et al,<sup><xref ref-type="bibr" rid="bibr166-0885066610393634">166</xref></sup> which has shown a less dense sympathetic innervation of the vertebrobasilar compared to the internal carotid system, Schwarz et al concluded that the vertebrobasilar system is more likely to be affected by increases in blood pressure and more susceptible to breakthrough of the upper limits of autoregulation. A newer study aiming at quantification of perivascular nerve fibres in human basal cerebral arteries has, however, shown exactly the opposite relation of innervation density in the circle of Willis, namely a higher perivascular sympathetic nerve density in the PCA and the posterior communicating artery (PCom), as compared to the rest of the basal cerebral arteries.<sup><xref ref-type="bibr" rid="bibr167-0885066610393634">167</xref></sup> The authors used a methodology of histologic preparation, which probably allows better representation of perivascular nerve fibers, especially of fibers within deeper layers of the vessel wall, as compared to the method used by Edvinsson et al.<sup><xref ref-type="bibr" rid="bibr166-0885066610393634">166</xref></sup> This finding allows the speculation that the higher density of sympathetic innervation of the PCA may contribute to increased vasoconstriction, hypoperfusion, and subsequent cerebral edema in the setting of endothelial injury in this part of the cerebral vasculature. This explanation would then better fit into the hypothesis of hypoperfusion as the central mechanism in the pathogenesis of PRES. The number of studies quantitatively investigating innervation density in human cerebral arteries is, however, still too small, the results controversial, and the correlation of those findings to clinical, imaging features, and hypotheses on the pathogenesis of a complex condition like PRES remains speculative. The repeated reports of different findings in the anterior and posterior parts of cerebral circulation, including in vivo functional studies using transcranial Doppler sonography,<sup><xref ref-type="bibr" rid="bibr168-0885066610393634">168</xref></sup> however, indicate the possible role of different innervation and vascular reactivity in the development of the imaging patterns in PRES.</p>
</sec>
<sec id="section9-0885066610393634">
<title>Prognosis and Treatment of PRES</title>
<sec id="section10-0885066610393634">
<title>Natural History</title>
<p>With timely institution of adequate treatment, PRES is usually completely reversible within several days to several weeks.<sup><xref ref-type="bibr" rid="bibr1-0885066610393634">1</xref>,<xref ref-type="bibr" rid="bibr74-0885066610393634">74</xref>,<xref ref-type="bibr" rid="bibr157-0885066610393634">157</xref></sup> Incomplete recovery has, however, also been reported under adequate therapy.<sup><xref ref-type="bibr" rid="bibr19-0885066610393634">19</xref>,<xref ref-type="bibr" rid="bibr154-0885066610393634">154</xref>,<xref ref-type="bibr" rid="bibr169-0885066610393634">169</xref></sup> In a recent long-term follow-up report on patients with PRES, in approximately 25% of the cases, abnormalities on imaging did not resolve completely and clinical improvement often preceded improvement on imaging.<sup><xref ref-type="bibr" rid="bibr19-0885066610393634">19</xref></sup> Similar results have been reported in women with eclampsia within several months from the event.<sup><xref ref-type="bibr" rid="bibr74-0885066610393634">74</xref></sup> When studied 7 years postpartum, 40% of formerly eclamptic women have shown white matter lesions on imaging, as compared to 17% of patients with no eclampsia.<sup><xref ref-type="bibr" rid="bibr74-0885066610393634">74</xref></sup> It is important to point out that reversibility of PRES is not spontaneous and delay in diagnosis and treatment may lead to permanent damage to affected areas of the brain.<sup><xref ref-type="bibr" rid="bibr10-0885066610393634">10</xref>,<xref ref-type="bibr" rid="bibr25-0885066610393634">25</xref>,<xref ref-type="bibr" rid="bibr170-0885066610393634">170</xref>,<xref ref-type="bibr" rid="bibr171-0885066610393634">171</xref></sup> Ischemia represents one of the major complications of PRES, occurring typically in the posterior border zone between the territories of the middle and posterior cerebral arteries.<sup><xref ref-type="bibr" rid="bibr25-0885066610393634">25</xref>,<xref ref-type="bibr" rid="bibr46-0885066610393634">46</xref></sup> Patients with multiple seizures in the course of PRES are at an especially high risk of developing infarction.<sup><xref ref-type="bibr" rid="bibr74-0885066610393634">74</xref>,<xref ref-type="bibr" rid="bibr169-0885066610393634">169</xref></sup> When hemorrhage occurs in PRES, focal parenchymal bleedings most likely lead to permanent clinical symptoms, as compared to minute, or sulcal bleeding.<sup><xref ref-type="bibr" rid="bibr36-0885066610393634">36</xref></sup>
</p>
<p>Epilepsy may represent another long-term complication of PRES. Patients with hippocampal sclerosis, or permanent focal changes and temporal lobe epilepsy, which has developed months to years after an episode of PRES, have been reported.<sup><xref ref-type="bibr" rid="bibr154-0885066610393634">154</xref>,<xref ref-type="bibr" rid="bibr172-0885066610393634">172</xref>,<xref ref-type="bibr" rid="bibr173-0885066610393634">173</xref></sup> It appears plausible, that lesions in PRES, which evolve into permanently damaged areas, may cause seizures in the long-term course. The development of hippocampal sclerosis after PRES, however, may also be coincidental and this issue remains controversial.<sup><xref ref-type="bibr" rid="bibr173-0885066610393634">173</xref></sup>
</p>
<p>To date, no data are available on the long-term neurocognitive consequences of PRES. Theoretically, the presence of permanent cerebral lesions in a considerable part of the patients who had suffered PRES may be reflected in a certain level of cognitive dysfunction. In a study using a questionnaire for cognitive functioning, formerly eclamptic women indeed reported cognitive impairment several years after complicated pregnancy.<sup><xref ref-type="bibr" rid="bibr174-0885066610393634">174</xref></sup> Objective neurocognitive testing performed in women several months after preeclampsia has also shown presence of cognitive deficits in such patients.<sup><xref ref-type="bibr" rid="bibr175-0885066610393634">175</xref></sup>
</p>
<p>Recurrence of PRES has been infrequently documented in single-case reports. Relapsing PRES has been reported in patients after solid organ transplantation, chemotherapy, allo-BMT, autoimmune disease, sickle cell disease, and in a patient with a mitochondrial disorder.<sup><xref ref-type="bibr" rid="bibr19-0885066610393634">19</xref>,<xref ref-type="bibr" rid="bibr54-0885066610393634">54</xref>,<xref ref-type="bibr" rid="bibr82-0885066610393634">82</xref>,<xref ref-type="bibr" rid="bibr97-0885066610393634">97</xref>,<xref ref-type="bibr" rid="bibr176-0885066610393634">176</xref>,<xref ref-type="bibr" rid="bibr177-0885066610393634">177</xref></sup> Multiple episodes of PRES in a single patient have been reported in children with renal disease<sup><xref ref-type="bibr" rid="bibr178-0885066610393634">178</xref></sup> and in a patient with SLE, for a total of 4 recurrent episodes of PRES that have been documented.<sup><xref ref-type="bibr" rid="bibr53-0885066610393634">53</xref></sup>
</p>
</sec>
<sec id="section11-0885066610393634">
<title>Differential Diagnosis and Treatment</title>
<p>The differential diagnosis of PRES includes a wide variety of acute neurological disorders with different etiologies. Several important conditions with prognostic and therapeutic implications should be considered: ischemic stroke and cerebral sinus thrombosis are usually easily ruled out by MRI and MR angiography. Inflammatory diseases, such as infectious (eg, viral) encephalitis, or autoimmune diseases like acute disseminated encephalomyelitis, can be excluded by cerebrospinal fluid examinations or negative bacteriological and virological tests. Other rare diseases, like mitochondrial disorders, or cerebral autosomal dominant arteriopathy with stroke and ischemic leukoencephalopathy (CADASIL), may also mimic the clinical and radiological appearance of PRES.<sup><xref ref-type="bibr" rid="bibr13-0885066610393634">13</xref></sup>
</p>
<p>There are several important aspects in the treatment of PRES: (i) the removal or reduction of the causative drug, (ii) aggressive management of blood pressure if hypertension is present, (iii) treatment of seizures and SE, and (iv) consideration of delivery by cesarean section in pregnant women with refractory symptoms.<sup><xref ref-type="bibr" rid="bibr13-0885066610393634">13</xref></sup> PRES is best managed in the setting of a neurocritical care unit with the possibility of close consultation with other specialties according to the underlying systemic condition, for example, oncology, rheumatology, obstetric critical care. Clinical and operative monitoring, that is, invasive blood pressure monitoring, monitoring of airways and oxygenation, and electroencephalographic monitoring in patients with seizures, are essential in the acute phase of PRES. Intubation and mechanic ventilation may be necessary in up to 39% of patients.<sup><xref ref-type="bibr" rid="bibr11-0885066610393634">11</xref></sup> General management also includes maintenance of homeostasis, sufficient hydration and arterial oxygenation, correction of hypoglycaemia, electrolyte disturbances, or coagulopathy.</p>
<p>Treatment of elevated blood pressure is considered central in the management of PRES. Generally, the goal of treatment is the reduction of mean blood pressure to premorbid levels. Intravenous antihypertensive drugs should be preferably used and blood pressure should be monitored with an arterial catheter. Intravenous nicardipine (5-15 mg/h) and labetalol (2-3 mg/min) are considered first-line medications in PRES.<sup><xref ref-type="bibr" rid="bibr13-0885066610393634">13</xref></sup> Hydralazine and diazoxide may also be used for antihypertensive treatment. As nitroglycerine has been reported to aggravate cerebral edema in PRES, it should not be primarily used in such patients.<sup><xref ref-type="bibr" rid="bibr179-0885066610393634">179</xref></sup>
</p>
<p>Too rapid correction of hypertension in pregnant women should be avoided in order to avert compromised uteroplacental blood flow.<sup><xref ref-type="bibr" rid="bibr13-0885066610393634">13</xref>,<xref ref-type="bibr" rid="bibr171-0885066610393634">171</xref></sup> The aim of the therapy in such patients is to lower the mean arterial pressure by no more than 15% to 25%. Antihypertensive treatment is usually recommended for sustained systolic blood pressure values of more than 160 mm Hg and diastolic blood pressure of at least 110 mm Hg.<sup><xref ref-type="bibr" rid="bibr180-0885066610393634">180</xref>,<xref ref-type="bibr" rid="bibr181-0885066610393634">181</xref></sup> Small reductions in blood pressure in the first 60 minutes with a target systolic value of approximately 140 to 155 mmHg and/or diastolic value of 90 to 105 mmHg have been recommended.<sup><xref ref-type="bibr" rid="bibr182-0885066610393634">182</xref></sup> Both intravenous hydralazine and labetalol have been shown to be safe for the management of hypertension in women with preeclampsia–eclampsia. Angiotensin-converting enzyme inhibitors should be avoided in pregnant women, because of their toxic effects on the fetal kidney.<sup><xref ref-type="bibr" rid="bibr183-0885066610393634">183</xref></sup>
</p>
<p>Status epilepticus is a neurologic emergency, in which a single generalized epileptic seizure does not cease within 5 minutes of onset, or recurrent epileptic seizures occur without complete clinical or electroencephalographic recovery between the single events. A focal SE is considered present if a focal seizure continues for more than 30 minutes.<sup><xref ref-type="bibr" rid="bibr184-0885066610393634">184</xref></sup> Generalized SE has a mortality of up to 40% depending on the underlying condition and duration. Therefore, this condition particularly requires immediate, aggressive, and effective treatment in order to prevent neuronal damage or death.<sup><xref ref-type="bibr" rid="bibr185-0885066610393634">185</xref></sup> After initial control of cardiorespiratory function and blood glucose level, the first-line treatment of SE consists of benzodiazepines, most commonly diazepam or lorazepam.<sup><xref ref-type="bibr" rid="bibr185-0885066610393634">185</xref></sup> Lorazepam is administered intravenously in boluses of 2 mg given slowly over 2 to 5 minutes, up to a cumulative dose of 10 mg. This treatment is usually followed by administration of second-line drugs such as phenytoin (15-18 mg/kg initially, maximal injection speed 50 mg/min) if SE persists after 20 minutes. In most countries, phenytoin is approved for the first-line treatment of SE. Third-line treatment of refractory SE usually consists of coma induction using anesthetics, such as propofol, midazolam, or barbiturates.<sup><xref ref-type="bibr" rid="bibr185-0885066610393634">185</xref></sup>
</p>
<p>In pregnant women with eclampsia, magnesium sulfate has been shown to be effective in treatment and prevention of eclamptic seizures compared to traditional antiepileptic drugs, such as diazepam or phenytoin.<sup><xref ref-type="bibr" rid="bibr186-0885066610393634">186</xref></sup>
</p>
</sec>
</sec>
<sec id="section12-0885066610393634">
<title>Conclusion</title>
<p>Since its description in 1996, many reports on PRES have accumulated in the literature. Although the pathophysiology of this condition has not been sufficiently elucidated yet, its clinical features and radiological appearance have been well documented. For the critical care physician, awareness of PRES is important, because immediate diagnosis and treatment initiation have the potential to result in a very good outcome, whereas delay in adequate therapy can lead to permanent neurological sequelae.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors thank Dr Marios Psychogios and Prof Michael Knauth from the Neuroradiology Department of the University of Göttingen, Germany, for kindly providing the images for this article.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0885066610393634">
<p>The author(s) declared no conflicts of interest with respect to the authorship and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0885066610393634">
<p>The author(s) received no financial support for the research and/or authorship of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0885066610393634">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinchey</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chaves</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Appignani</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>A reversible posterior leukoencephalopathy syndrome</article-title>. <source>N Engl J Med</source>. <year>1996</year>;<volume>334</volume>(<issue>8</issue>):<fpage>494</fpage>–<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr2-0885066610393634">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Bravo</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Klufas</surname>
<given-names>RA</given-names>
</name>
<etal/>
</person-group>. <article-title>Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases</article-title>. <source>AJR Am J Roentgenol</source>. <year>1995</year>;<volume>165</volume>(<issue>3</issue>):<fpage>627</fpage>–<lpage>631</lpage>.</citation>
</ref>
<ref id="bibr3-0885066610393634">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Kalina</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases</article-title>. <source>AJR Am J Roentgenol</source>. <year>1992</year>;<volume>159</volume>(<issue>2</issue>):<fpage>379</fpage>–<lpage>383</lpage>.</citation>
</ref>
<ref id="bibr4-0885066610393634">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hauser</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Lacey</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>MR.</given-names></name></person-group> <article-title>Hypertensive encephalopathy. Magnetic resonance imaging demonstration of reversible cortical and white matter lesions</article-title>. <source>Arch Neurol</source>. <year>1988</year>;<volume>45</volume>(<issue>10</issue>):<fpage>1078</fpage>–<lpage>1083</lpage>.</citation>
</ref>
<ref id="bibr5-0885066610393634">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>RB.</given-names></name></person-group> <article-title>A reversible posterior leukoencephalopathy syndrome</article-title>. <source>N Engl J Med</source>. <year>1996</year>;<volume>334</volume>(<issue>26</issue>):<fpage>1743</fpage>; <comment>author reply 1746</comment>
</citation>
</ref>
<ref id="bibr6-0885066610393634">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pavlakis</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kalina</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chandra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>D.</given-names></name></person-group> <article-title>Occipital-parietal encephalopathy: a new name for an old syndrome</article-title>. <source>Pediatr Neurol</source>. <year>1997</year>;<volume>16</volume>(<issue>2</issue>):<fpage>145</fpage>–<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr7-0885066610393634">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narbone</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Musolino</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Granata</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mazzu</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Abbate</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ferlazzo</surname>
<given-names>E.</given-names></name></person-group> <article-title>PRES: posterior or potentially reversible encephalopathy syndrome?</article-title> <source>Neurol Sci</source>. <year>2006</year>;<volume>27</volume>(<issue>3</issue>):<fpage>187</fpage>–<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr8-0885066610393634">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maizlin</surname>
<given-names>ZV</given-names>
</name>
<name>
<surname>Ghandehari</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Maizels</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Linguistic history of posterior reversible encephalopathy syndrome: mirror of developing knowledge</article-title>. <source>J Neuroimaging</source>. <year>2009</year>. <comment>doi:10.1111/j.1552-6569. 2009.00395.x</comment>.</citation>
</ref>
<ref id="bibr9-0885066610393634">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartynski</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Boardman</surname>
<given-names>JF.</given-names></name></person-group> <article-title>Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2007</year>;<volume>28</volume>(<issue>7</issue>):<fpage>1320</fpage>–<lpage>1327</lpage>.</citation>
</ref>
<ref id="bibr10-0885066610393634">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casey</surname>
<given-names>SO</given-names>
</name>
<name>
<surname>Sampaio</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Truwit</surname>
<given-names>CL.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2000</year>;<volume>21</volume>(<issue>7</issue>):<fpage>1199</fpage>–<lpage>1206</lpage>.</citation>
</ref>
<ref id="bibr11-0885066610393634">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>VH</given-names>
</name>
<name>
<surname>Wijdicks</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Manno</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Rabinstein</surname>
<given-names>AA.</given-names></name></person-group> <article-title>Clinical spectrum of reversible posterior leukoencephalopathy syndrome</article-title>. <source>Arch Neurol</source>. <year>2008</year>;<volume>65</volume>(<issue>2</issue>):<fpage>205</fpage>–<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr12-0885066610393634">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garg</surname>
<given-names>RK.</given-names></name></person-group> <article-title>Posterior leukoencephalopathy syndrome</article-title>. <source>Postgrad Med J</source>. <year>2001</year>;<volume>77</volume>(<issue>903</issue>):<fpage>24</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr13-0885066610393634">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Servillo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bifulco</surname>
<given-names>F</given-names>
</name>
<name>
<surname>De Robertis</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Posterior reversible encephalopathy syndrome in intensive care medicine</article-title>. <source>Intensive Care Med</source>. <year>2007</year>;<volume>33</volume>(<issue>2</issue>):<fpage>230</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr14-0885066610393634">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartynski</surname>
<given-names>WS.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2008</year>;<volume>29</volume>(<issue>6</issue>):<fpage>1036</fpage>–<lpage>1042</lpage>.</citation>
</ref>
<ref id="bibr15-0885066610393634">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartynski</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Boardman</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Zeigler</surname>
<given-names>ZR</given-names>
</name>
<name>
<surname>Shadduck</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Lister</surname>
<given-names>J.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome in infection, sepsis, and shock</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2006</year>;<volume>27</volume>(<issue>10</issue>):<fpage>2179</fpage>–<lpage>2190</lpage>.</citation>
</ref>
<ref id="bibr16-0885066610393634">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartynski</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Boardman</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>JW.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome after solid organ transplantation</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2008</year>;<volume>29</volume>(<issue>5</issue>):<fpage>924</fpage>–<lpage>930</lpage>.</citation>
</ref>
<ref id="bibr17-0885066610393634">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartynski</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Grabb</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Zeigler</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>DF.</given-names></name></person-group> <article-title>Watershed imaging features and clinical vascular injury in cyclosporin A neurotoxicity</article-title>. <source>J Comput Assist Tomogr</source>. <year>1997</year>;<volume>21</volume>(<issue>6</issue>):<fpage>872</fpage>–<lpage>880</lpage>.</citation>
</ref>
<ref id="bibr18-0885066610393634">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartynski</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Zeigler</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Spearman</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shadduck</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Lister</surname>
<given-names>J.</given-names></name></person-group> <article-title>Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2001</year>;<volume>22</volume>(<issue>10</issue>):<fpage>1901</fpage>–<lpage>1914</lpage>.</citation>
</ref>
<ref id="bibr19-0885066610393634">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roth</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ferbert</surname>
<given-names>A.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome—long-term follow-up</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2010</year>;<volume>81</volume>(<issue>7</issue>):<fpage>773</fpage>–<lpage>777</lpage>.</citation>
</ref>
<ref id="bibr20-0885066610393634">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahn</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>You</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>SL</given-names>
</name>
<etal/>
</person-group>. <article-title>Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping</article-title>. <source>Neuroradiology</source>. <year>2004</year>;<volume>46</volume>(<issue>12</issue>):<fpage>978</fpage>–<lpage>983</lpage>.</citation>
</ref>
<ref id="bibr21-0885066610393634">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Oppenheim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Meder</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Mas</surname>
<given-names>JL.</given-names></name></person-group> <article-title>Neuroimaging in posterior reversible encephalopathy syndrome</article-title>. <source>J Neuroimaging</source>. <year>2004</year>;<volume>14</volume>(<issue>2</issue>):<fpage>89</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr22-0885066610393634">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Mulkern</surname>
<given-names>RV</given-names>
</name>
<name>
<surname>Gudbjartsson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jolesz</surname>
<given-names>F.</given-names></name></person-group> <article-title>Diffusion-weighted MR imaging in hypertensive encephalopathy: clues to pathogenesis</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1998</year>;<volume>19</volume>(<issue>5</issue>):<fpage>859</fpage>–<lpage>862</lpage>.</citation>
</ref>
<ref id="bibr23-0885066610393634">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ugurel</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Hayakawa</surname>
<given-names>M.</given-names></name></person-group> <article-title>Implications of post-gadolinium MRI results in 13 cases with posterior reversible encephalopathy syndrome</article-title>. <source>Eur J Radiol</source>. <year>2005</year>;<volume>53</volume>(<issue>3</issue>):<fpage>441</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr24-0885066610393634">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKinney</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Short</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Truwit</surname>
<given-names>CL</given-names>
</name>
<etal/>
</person-group>. <article-title>Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings</article-title>. <source>AJR Am J Roentgenol</source>. <year>2007</year>;<volume>189</volume>(<issue>4</issue>):<fpage>904</fpage>–<lpage>912</lpage>.</citation>
</ref>
<ref id="bibr25-0885066610393634">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Covarrubias</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Luetmer</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Campeau</surname>
<given-names>NG.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2002</year>;<volume>23</volume>(<issue>6</issue>):<fpage>1038</fpage>–<lpage>1048</lpage>.</citation>
</ref>
<ref id="bibr26-0885066610393634">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ay</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Buonanno</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>PW</given-names>
</name>
<etal/>
</person-group>. <article-title>Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI</article-title>. <source>Neurology</source>. <year>1998</year>;<volume>51</volume>(<issue>5</issue>):<fpage>1369</fpage>–<lpage>1376</lpage>.</citation>
</ref>
<ref id="bibr27-0885066610393634">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benziada-Boudour</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kremer</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Posterior reversible encephalopathy syndrome: a case of unusual diffusion-weighted MR images</article-title>. <source>J Neuroradiol</source>. <year>2009</year>;<volume>36</volume>(<issue>2</issue>):<fpage>102</fpage>–<lpage>105</lpage>.</citation>
</ref>
<ref id="bibr28-0885066610393634">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sengar</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Dhanuka</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>K.</given-names></name></person-group> <article-title>MR imaging, MR angiography, and MR spectroscopy of the brain in eclampsia</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1997</year>;<volume>18</volume>(<issue>8</issue>):<fpage>1485</fpage>–<lpage>1490</lpage>.</citation>
</ref>
<ref id="bibr29-0885066610393634">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eichler</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wityk</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Beauchamp</surname>
<given-names>NJ</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Barker</surname>
<given-names>PB.</given-names></name></person-group> <article-title>Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2002</year>;<volume>23</volume>(<issue>5</issue>):<fpage>833</fpage>–<lpage>837</lpage>.</citation>
</ref>
<ref id="bibr30-0885066610393634">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russell</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Nassif</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Cacayorin</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Awwad</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Perman</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Dunphy</surname>
<given-names>F.</given-names></name></person-group> <article-title>Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings</article-title>. <source>Magn Reson Imaging</source>. <year>2001</year>;<volume>19</volume>(<issue>1</issue>):<fpage>129</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr31-0885066610393634">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Shon</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SS.</given-names></name></person-group> <article-title>Serial MR spectroscopy in relapsing reversible posterior leukoencephalopathy syndrome</article-title>. <source>Neurologist</source>. <year>2009</year>;<volume>15</volume>(<issue>6</issue>):<fpage>338</fpage>–<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr32-0885066610393634">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller-Mang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pirker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Prchla</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Prayer</surname>
<given-names>D.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance?</article-title> <source>Neuroradiology</source>. <year>2009</year>;<volume>51</volume>(<issue>6</issue>):<fpage>373</fpage>–<lpage>383</lpage>.</citation>
</ref>
<ref id="bibr33-0885066610393634">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>RB.</given-names></name></person-group> <article-title>Hyperperfusion encephalopathies: hypertensive encephalopathy and related conditions</article-title>. <source>Neurologist</source>. <year>2002</year>;<volume>8</volume>(<issue>1</issue>):<fpage>22</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr34-0885066610393634">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>BV</given-names>
</name>
<name>
<surname>Egelhoff</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>RJ.</given-names></name></person-group> <article-title>Hypertensive encephalopathy in children</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1997</year>;<volume>18</volume>(<issue>1</issue>):<fpage>101</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr35-0885066610393634">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weier</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fluri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kos</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gass</surname>
<given-names>A.</given-names></name></person-group> <article-title>Postcontrast flair MRI demonstrates blood-brain barrier dysfunction in PRES</article-title>. <source>Neurology</source>. <year>2009</year>;<volume>72</volume>(<issue>8</issue>):<fpage>760</fpage>–<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr36-0885066610393634">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hefzy</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Bartynski</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Boardman</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Lacomis</surname>
<given-names>D.</given-names></name></person-group> <article-title>Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2009</year>;<volume>30</volume>(<issue>7</issue>):<fpage>1371</fpage>–<lpage>1379</lpage>.</citation>
</ref>
<ref id="bibr37-0885066610393634">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singhal</surname>
<given-names>AB.</given-names></name></person-group> <article-title>Postpartum angiopathy with reversible posterior leukoencephalopathy</article-title>. <source>Arch Neurol</source>. <year>2004</year>;<volume>61</volume>(<issue>3</issue>):<fpage>411</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr38-0885066610393634">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smeda</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Payne</surname>
<given-names>GW.</given-names></name></person-group> <article-title>Alterations in autoregulatory and myogenic function in the cerebrovasculature of Dahl salt-sensitive rats</article-title>. <source>Stroke</source>. <year>2003</year>;<volume>34</volume>(<issue>6</issue>):<fpage>1484</fpage>–<lpage>1490</lpage>.</citation>
</ref>
<ref id="bibr39-0885066610393634">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Apollon</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Norwitz</surname>
<given-names>ER.</given-names></name></person-group> <article-title>Cortical blindness in severe preeclampsia: computed tomography, magnetic resonance imaging, and single-photon-emission computed tomography findings</article-title>. <source>Obstet Gynecol</source>. <year>2000</year>;<volume>95</volume>(<issue>6 pt 2</issue>):<fpage>1017</fpage>–<lpage>1019</lpage>.</citation>
</ref>
<ref id="bibr40-0885066610393634">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mulkern</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vajapeyam</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kacher</surname>
<given-names>DF.</given-names></name></person-group> <article-title>Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2009</year>;<volume>30</volume>(<issue>2</issue>):<fpage>E19</fpage>; <comment>author reply E20</comment>.</citation>
</ref>
<ref id="bibr41-0885066610393634">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartynski</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Boardman</surname>
<given-names>JF.</given-names></name></person-group> <article-title>Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2008</year>;<volume>29</volume>(<issue>3</issue>):<fpage>447</fpage>–<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr42-0885066610393634">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Fuh</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Lirng</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>PM.</given-names></name></person-group> <article-title>Prolonged reversible vasospasm in cyclosporin A-induced encephalopathy</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2003</year>;<volume>24</volume>(<issue>1</issue>):<fpage>102</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr43-0885066610393634">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brubaker</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YZ</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Castillo</surname>
<given-names>M.</given-names></name></person-group> <article-title>Hemodynamic and permeability changes in posterior reversible encephalopathy syndrome measured by dynamic susceptibility perfusion-weighted MR imaging</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2005</year>;<volume>26</volume>(<issue>4</issue>):<fpage>825</fpage>–<lpage>830</lpage>.</citation>
</ref>
<ref id="bibr44-0885066610393634">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engelter</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Petrella</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Alberts</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Provenzale</surname>
<given-names>JM.</given-names></name></person-group> <article-title>Assessment of cerebral microcirculation in a patient with hypertensive encephalopathy using MR perfusion imaging</article-title>. <source>AJR Am J Roentgenol</source>. <year>1999</year>;<volume>173</volume>(<issue>6</issue>):<fpage>1491</fpage>–<lpage>1493</lpage>.</citation>
</ref>
<ref id="bibr45-0885066610393634">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naidu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Moodley</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Corr</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>M.</given-names></name></person-group> <article-title>Single photon emission and cerebral computerised tomographic scan and transcranial Doppler sonographic findings in eclampsia</article-title>. <source>Br J Obstet Gynaecol</source>. <year>1997</year>;<volume>104</volume>(<issue>10</issue>):<fpage>1165</fpage>–<lpage>1172</lpage>.</citation>
</ref>
<ref id="bibr46-0885066610393634">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casey</surname>
<given-names>SO</given-names>
</name>
<name>
<surname>McKinney</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Teksam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Truwit</surname>
<given-names>CL.</given-names></name></person-group> <article-title>CT perfusion imaging in the management of posterior reversible encephalopathy</article-title>. <source>Neuroradiology</source>. <year>2004</year>;<volume>46</volume>(<issue>4</issue>):<fpage>272</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr47-0885066610393634">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Hinshaw</surname>
<given-names>DB</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Will</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Hasso</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>JR.</given-names></name></person-group> <article-title>CT and angiographic correlation of severe neurological disease in toxemia of pregnancy</article-title>. <source>Neuroradiology</source>. <year>1988</year>;<volume>30</volume>(<issue>1</issue>):<fpage>59</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr48-0885066610393634">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trommer</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Homer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mikhael</surname>
<given-names>MA.</given-names></name></person-group> <article-title>Cerebral vasospasm and eclampsia</article-title>. <source>Stroke</source>. <year>1988</year>;<volume>19</volume>(<issue>3</issue>):<fpage>326</fpage>–<lpage>329</lpage>.</citation>
</ref>
<ref id="bibr49-0885066610393634">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Will</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Hinshaw</surname>
<given-names>DB</given-names>
<suffix>Jr</suffix>
</name>
<etal/>
</person-group>. <article-title>Cerebral vasoconstriction in toxemia</article-title>. <source>Neurology</source>. <year>1987</year>;<volume>37</volume>(<issue>9</issue>):<fpage>1555</fpage>–<lpage>1557</lpage>.</citation>
</ref>
<ref id="bibr50-0885066610393634">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartynski</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Sanghvi</surname>
<given-names>A.</given-names></name></person-group> <article-title>Neuroimaging of delayed eclampsia. Report of 3 cases and review of the literature</article-title>. <source>J Comput Assist Tomogr</source>. <year>2003</year>;<volume>27</volume>(<issue>5</issue>):<fpage>699</fpage>–<lpage>713</lpage>.</citation>
</ref>
<ref id="bibr51-0885066610393634">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geraghty</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Hoch</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Vinters</surname>
<given-names>HV.</given-names></name></person-group> <article-title>Fatal puerperal cerebral vasospasm and stroke in a young woman</article-title>. <source>Neurology</source>. <year>1991</year>;<volume>41</volume>(<issue>7</issue>):<fpage>1145</fpage>–<lpage>1147</lpage>.</citation>
</ref>
<ref id="bibr52-0885066610393634">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ito</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Inagawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Utsu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bun</surname>
<given-names>T.</given-names></name></person-group> <article-title>MR angiography of cerebral vasospasm in preeclampsia</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1995</year>;<volume>16</volume>(<issue>6</issue>):<fpage>1344</fpage>–<lpage>1346</lpage>.</citation>
</ref>
<ref id="bibr53-0885066610393634">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thaipisuttikul</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Phanthumchinda</surname>
<given-names>K.</given-names></name></person-group> <article-title>Recurrent reversible posterior leukoencephalopathy in a patient with systemic lupus erythematosus</article-title>. <source>J Neurol</source>. <year>2005</year>;<volume>252</volume>(<issue>2</issue>):<fpage>230</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr54-0885066610393634">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweany</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Bartynski</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Boardman</surname>
<given-names>JF.</given-names></name></person-group> <article-title>“Recurrent” posterior reversible encephalopathy syndrome: report of 3 cases—PRES can strike twice!</article-title>. <source>J Comput Assist Tomogr</source>. <year>2007</year>;<volume>31</volume>(<issue>1</issue>):<fpage>148</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr55-0885066610393634">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fisher</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maister</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>R.</given-names></name></person-group> <article-title>Hypertensive encephalopathy: diffuse reversible white matter CT abnormalities</article-title>. <source>Ann Neurol</source>. <year>1985</year>;<volume>18</volume>(<issue>2</issue>):<fpage>268</fpage>–<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr56-0885066610393634">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rail</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Perkin</surname>
<given-names>GD.</given-names></name></person-group> <article-title>Computerized tomographic appearance of hypertensive encephalopathy</article-title>. <source>Arch Neurol</source>. <year>1980</year>;<volume>37</volume>(<issue>5</issue>):<fpage>310</fpage>–<lpage>311</lpage>.</citation>
</ref>
<ref id="bibr57-0885066610393634">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weingarten</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Barbut</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Filippi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>RD.</given-names></name></person-group> <article-title>Acute hypertensive encephalopathy: findings on spin-echo and gradient-echo MR imaging</article-title>. <source>AJR Am J Roentgenol</source>. <year>1994</year>;<volume>162</volume>(<issue>3</issue>):<fpage>665</fpage>–<lpage>670</lpage>.</citation>
</ref>
<ref id="bibr58-0885066610393634">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Lui</surname>
<given-names>TN.</given-names></name></person-group> <article-title>Hypertension-induced cerebellar encephalopathy and hydrocephalus in a male</article-title>. <source>Pediatr Neurol</source>. <year>2006</year>;<volume>34</volume>(<issue>1</issue>):<fpage>72</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr59-0885066610393634">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwong</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>CY.</given-names></name></person-group> <article-title>CT appearance in hypertensive encephalopathy</article-title>. <source>Neuroradiology</source>. <year>1987</year>;<volume>29</volume>(<issue>2</issue>):<fpage>215</fpage>.</citation>
</ref>
<ref id="bibr60-0885066610393634">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weingarten</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Whelan</surname>
<given-names>MA.</given-names></name></person-group> <article-title>Computed tomographic changes of hypertensive encephalopathy</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1985</year>;<volume>6</volume>(<issue>3</issue>):<fpage>395</fpage>–<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr61-0885066610393634">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colosimo</surname>
<given-names>C</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Fileni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moschini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guerrini</surname>
<given-names>P.</given-names></name></person-group> <article-title>CT findings in eclampsia</article-title>. <source>Neuroradiology</source>. <year>1985</year>;<volume>27</volume>(<issue>4</issue>):<fpage>313</fpage>–<lpage>317</lpage>.</citation>
</ref>
<ref id="bibr62-0885066610393634">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naheedy</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Biller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schiffer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Azar-Kia</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gianopoulous</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zarandy</surname>
<given-names>S.</given-names></name></person-group> <article-title>Toxemia of pregnancy: cerebral CT findings</article-title>. <source>J Comput Assist Tomogr</source>. <year>1985</year>;<volume>9</volume>(<issue>3</issue>):<fpage>497</fpage>–<lpage>501</lpage>.</citation>
</ref>
<ref id="bibr63-0885066610393634">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waldron</surname>
<given-names>RL</given-names>
<suffix>II</suffix>
</name>
<name>
<surname>Abbott</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Vellody</surname>
<given-names>D.</given-names></name></person-group> <article-title>Computed tomography in preeclampsia-eclampsia syndrome</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1985</year>;<volume>6</volume>(<issue>3</issue>):<fpage>442</fpage>–<lpage>443</lpage>.</citation>
</ref>
<ref id="bibr64-0885066610393634">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rabinstein</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Falcone</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Forteza</surname>
<given-names>A.</given-names></name></person-group> <article-title>Diffusion-weighted imaging shows cytotoxic and vasogenic edema in eclampsia</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2001</year>;<volume>22</volume>(<issue>6</issue>):<fpage>1068</fpage>–<lpage>1070</lpage>.</citation>
</ref>
<ref id="bibr65-0885066610393634">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaefer</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Buonanno</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Schwamm</surname>
<given-names>LH.</given-names></name></person-group> <article-title>Diffusion-weighted imaging discriminates between cytotoxic and vasogenic edema in a patient with eclampsia</article-title>. <source>Stroke</source>. <year>1997</year>;<volume>28</volume>(<issue>5</issue>):<fpage>1082</fpage>–<lpage>1085</lpage>.</citation>
</ref>
<ref id="bibr66-0885066610393634">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raroque</surname>
<given-names>HG</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Orrison</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>GA.</given-names></name></person-group> <article-title>Neurologic involvement in toxemia of pregnancy: reversible MRI lesions</article-title>. <source>Neurology</source>. <year>1990</year>;<volume>40</volume>(<issue>1</issue>):<fpage>167</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr67-0885066610393634">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Clayman</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Sanchez-Ramos</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vines</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>L.</given-names></name></person-group> <article-title>Brain in eclampsia: MR imaging with clinical correlation</article-title>. <source>Radiology</source>. <year>1991</year>;<volume>180</volume>(<issue>2</issue>):<fpage>475</fpage>–<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr68-0885066610393634">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Feske</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Polak</surname>
<given-names>JF</given-names>
</name>
<etal/>
</person-group>. <article-title>Preeclampsia-eclampsia: clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy</article-title>. <source>Radiology</source>. <year>2000</year>;<volume>217</volume>(<issue>2</issue>):<fpage>371</fpage>–<lpage>376</lpage>.</citation>
</ref>
<ref id="bibr69-0885066610393634">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marik</surname>
<given-names>PE.</given-names></name></person-group> <article-title>Hypertensive disorders of pregnancy</article-title>. <source>Postgrad Med</source>. <year>2009</year>;<volume>121</volume>(<issue>2</issue>):<fpage>69</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr70-0885066610393634">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Powell</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>MJ.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome (PRES) in a thirty-six-week gestation eclamptic</article-title>. <source>J Emerg Med</source>. <year>2007</year>;<volume>33</volume>(<issue>4</issue>):<fpage>377</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr71-0885066610393634">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Servillo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Apicella</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Striano</surname>
<given-names>P.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome (PRES) in the parturient with preeclampsia after inadvertent dural puncture</article-title>. <source>Int J Obstet Anesth</source>. <year>2008</year>;<volume>17</volume>(<issue>1</issue>):<fpage>88</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr72-0885066610393634">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torrillo</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Bronster</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Beilin</surname>
<given-names>Y.</given-names></name></person-group> <article-title>Delayed diagnosis of posterior reversible encephalopathy syndrome (PRES) in a parturient with preeclampsia after inadvertent dural puncture</article-title>. <source>Int J Obstet Anesth</source>. <year>2007</year>;<volume>16</volume>(<issue>2</issue>):<fpage>171</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr73-0885066610393634">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roth</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ferbert</surname>
<given-names>A.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome: is there a difference between pregnant and non-pregnant patients?</article-title> <source>Eur Neurol</source>. <year>2009</year>;<volume>62</volume>(<issue>3</issue>):<fpage>142</fpage>–<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr74-0885066610393634">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeeman</surname>
<given-names>GG.</given-names></name></person-group> <article-title>Neurologic complications of pre-eclampsia</article-title>. <source>Semin Perinatol</source>. <year>2009</year>;<volume>33</volume>(<issue>3</issue>):<fpage>166</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr75-0885066610393634">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okanloma</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Moodley</surname>
<given-names>J.</given-names></name></person-group> <article-title>Neurological complications associated with the pre-eclampsia/eclampsia syndrome</article-title>. <source>Int J Gynaecol Obstet</source>. <year>2000</year>;<volume>71</volume>(<issue>3</issue>):<fpage>223</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr76-0885066610393634">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isler</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Rinehart</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Terrone</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Magann</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>JN</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome</article-title>. <source>Am J Obstet Gynecol</source>. <year>1999</year>;<volume>181</volume>(<issue>4</issue>):<fpage>924</fpage>–<lpage>928</lpage>.</citation>
</ref>
<ref id="bibr77-0885066610393634">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sibai</surname>
<given-names>BM.</given-names></name></person-group> <article-title>Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases</article-title>. <source>Am J Obstet Gynecol</source>. <year>1990</year>;<volume>163</volume>(<issue>3</issue>):<fpage>1049</fpage>–<lpage>1054</lpage>; <comment>discussion 1054–1045</comment>.</citation>
</ref>
<ref id="bibr78-0885066610393634">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dekker</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Sibai</surname>
<given-names>BM.</given-names></name></person-group> <article-title>Etiology and pathogenesis of preeclampsia: current concepts</article-title>. <source>Am J Obstet Gynecol</source>. <year>1998</year>;<volume>179</volume>(<issue>5</issue>):<fpage>1359</fpage>–<lpage>1375</lpage>.</citation>
</ref>
<ref id="bibr79-0885066610393634">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delefosse</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Samain</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Helias</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Late onset of cortical blindness in a patient with severe preeclampsia related to retained placental fragments</article-title>. <source>Anesthesiology</source>. <year>2003</year>;<volume>98</volume>(<issue>1</issue>):<fpage>261</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr80-0885066610393634">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reece</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Frei-Lahr</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>JD</given-names>
</name>
<etal/>
</person-group>. <article-title>Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin</article-title>. <source>Bone Marrow Transplant</source>. <year>1991</year>;<volume>8</volume>(<issue>5</issue>):<fpage>393</fpage>–<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr81-0885066610393634">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kishi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Miyakoshi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kami</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Early central nervous system complications after reduced-intensity stem cell transplantation</article-title>. <source>Biol Blood Marrow Transplant</source>. <year>2004</year>;<volume>10</volume>(<issue>8</issue>):<fpage>561</fpage>–<lpage>568</lpage>.</citation>
</ref>
<ref id="bibr82-0885066610393634">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Beguelin</surname>
<given-names>GZ</given-names>
</name>
<name>
<surname>de Lima</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation</article-title>. <source>Br J Haematol</source>. <year>2003</year>;<volume>122</volume>(<issue>1</issue>):<fpage>128</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr83-0885066610393634">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimmer</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Hourihane</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>HZ</given-names>
</name>
<name>
<surname>Schriber</surname>
<given-names>JR.</given-names></name></person-group> <article-title>The effect of human leukocyte antigen disparity on cyclosporine neurotoxicity after allogeneic bone marrow transplantation</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1998</year>;<volume>19</volume>(<issue>4</issue>):<fpage>601</fpage>–<lpage>608</lpage>; <comment>discussion 609–610</comment>.</citation>
</ref>
<ref id="bibr84-0885066610393634">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanekiyo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Matsuda-Hashii</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children</article-title>. <source>Int J Hematol</source>. <year>2005</year>;<volume>81</volume>(<issue>3</issue>):<fpage>264</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr85-0885066610393634">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Groen</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Aksamit</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Rakela</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Forbes</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Krom</surname>
<given-names>RA.</given-names></name></person-group> <article-title>Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol</article-title>. <source>N Engl J Med</source>. <year>1987</year>;<volume>317</volume>(<issue>14</issue>):<fpage>861</fpage>–<lpage>866</lpage>.</citation>
</ref>
<ref id="bibr86-0885066610393634">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Truwit</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Denaro</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Lake</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>DeMarco</surname>
<given-names>T.</given-names></name></person-group> <article-title>MR imaging of reversible cyclosporin A-induced neurotoxicity</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1991</year>;<volume>12</volume>(<issue>4</issue>):<fpage>651</fpage>–<lpage>659</lpage>.</citation>
</ref>
<ref id="bibr87-0885066610393634">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>de Groen</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Aksamit</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Wiesner</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Garrity</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Krom</surname>
<given-names>RA.</given-names></name></person-group> <article-title>Cyclosporin A-induced reversible cortical blindness</article-title>. <source>J Clin Neuroophthalmol</source>. <year>1988</year>;<volume>8</volume>(<issue>4</issue>):<fpage>215</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr88-0885066610393634">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nussbaum</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Bitterman</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Hertz</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Bula</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Latchaw</surname>
<given-names>RE.</given-names></name></person-group> <article-title>Cyclosporine A toxicity presenting with acute cerebellar edema and brainstem compression. Case report</article-title>. <source>J Neurosurg</source>. <year>1995</year>;<volume>82</volume>(<issue>6</issue>):<fpage>1068</fpage>–<lpage>1070</lpage>.</citation>
</ref>
<ref id="bibr89-0885066610393634">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furukawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Terae</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Kaneko</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kamada</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Miyasaka</surname>
<given-names>K.</given-names></name></person-group> <article-title>MRI in seven cases of tacrolimus (FK-506) encephalopathy: utility of FLAIR and diffusion-weighted imaging</article-title>. <source>Neuroradiology</source>. <year>2001</year>;<volume>43</volume>(<issue>8</issue>):<fpage>615</fpage>–<lpage>621</lpage>.</citation>
</ref>
<ref id="bibr90-0885066610393634">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jarosz</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Howlett</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Bingham</surname>
<given-names>JB.</given-names></name></person-group> <article-title>Cyclosporine-related reversible posterior leukoencephalopathy: MRI</article-title>. <source>Neuroradiology</source>. <year>1997</year>;<volume>39</volume>(<issue>10</issue>):<fpage>711</fpage>–<lpage>715</lpage>.</citation>
</ref>
<ref id="bibr91-0885066610393634">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Small</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Fukui</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Bramblett</surname>
<given-names>GT</given-names>
</name>
<name>
<surname>Eidelman</surname>
<given-names>BH.</given-names></name></person-group> <article-title>Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506)</article-title>. <source>Ann Neurol</source>. <year>1996</year>;<volume>40</volume>(<issue>4</issue>):<fpage>575</fpage>–<lpage>580</lpage>.</citation>
</ref>
<ref id="bibr92-0885066610393634">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Appignani</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Bhadelia</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Blacklow</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Roland</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>RB</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity</article-title>. <source>AJR Am J Roentgenol</source>. <year>1996</year>;<volume>166</volume>(<issue>3</issue>):<fpage>683</fpage>–<lpage>688</lpage>.</citation>
</ref>
<ref id="bibr93-0885066610393634">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lanzino</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cloft</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hemstreet</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>West</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Alston</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ishitani</surname>
<given-names>M.</given-names></name></person-group> <article-title>Reversible posterior leukoencephalopathy following organ transplantation. Description of two cases</article-title>. <source>Clin Neurol Neurosurg</source>. <year>1997</year>;<volume>99</volume>(<issue>3</issue>):<fpage>222</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr94-0885066610393634">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimono</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Miki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Toyoda</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients</article-title>. <source>Eur Radiol</source>. <year>2003</year>;<volume>13</volume>(<issue>5</issue>):<fpage>986</fpage>–<lpage>993</lpage>.</citation>
</ref>
<ref id="bibr95-0885066610393634">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Besenski</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rumboldt</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Emovon</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Brain MR imaging abnormalities in kidney transplant recipients</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2005</year>;<volume>26</volume>(<issue>9</issue>):<fpage>2282</fpage>–<lpage>2289</lpage>.</citation>
</ref>
<ref id="bibr96-0885066610393634">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parvex</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pinsk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>O’Gorman</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Patenaude</surname>
<given-names>YG</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>IR.</given-names></name></person-group> <article-title>Reversible encephalopathy associated with tacrolimus in pediatric renal transplants</article-title>. <source>Pediatr Nephrol</source>. <year>2001</year>;<volume>16</volume>(<issue>7</issue>):<fpage>537</fpage>–<lpage>542</lpage>.</citation>
</ref>
<ref id="bibr97-0885066610393634">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reinohs</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Straube</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Berrouschot</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>A.</given-names></name></person-group> <article-title>Recurrent reversible cerebral edema after long term immunosuppression with tacrolimus</article-title>. <source>J Neurol</source>. <year>2002</year>;<volume>249</volume>(<issue>6</issue>):<fpage>780</fpage>–<lpage>781</lpage>.</citation>
</ref>
<ref id="bibr98-0885066610393634">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartynski</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Zeigler</surname>
<given-names>ZR</given-names>
</name>
<name>
<surname>Shadduck</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Lister</surname>
<given-names>J.</given-names></name></person-group> <article-title>Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2004</year>;<volume>25</volume>(<issue>2</issue>):<fpage>261</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr99-0885066610393634">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartynski</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Zeigler</surname>
<given-names>ZR</given-names>
</name>
<name>
<surname>Shadduck</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Lister</surname>
<given-names>J.</given-names></name></person-group> <article-title>Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation</article-title>. <source>Neurocrit Care</source>. <year>2005</year>;<volume>3</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr100-0885066610393634">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chohan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vij</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Adkins</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity</article-title>. <source>Br J Haematol</source>. <year>2003</year>;<volume>123</volume>(<issue>1</issue>):<fpage>110</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr101-0885066610393634">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Provenzale</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>ML.</given-names></name></person-group> <article-title>Reversible leukoencephalopathy associated with graft-versus-host disease: MR findings</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1996</year>;<volume>17</volume>(<issue>7</issue>):<fpage>1290</fpage>–<lpage>1294</lpage>.</citation>
</ref>
<ref id="bibr102-0885066610393634">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bonham</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fukui</surname>
<given-names>M.</given-names></name></person-group> <article-title>Immunosuppressive-associated leukoencephalopathy in organ transplant recipients</article-title>. <source>Transplantation</source>. <year>2000</year>;<volume>69</volume>(<issue>4</issue>):<fpage>467</fpage>–<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr103-0885066610393634">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wijdicks</surname>
<given-names>EF.</given-names></name></person-group> <article-title>Neurotoxicity of immunosuppressive drugs</article-title>. <source>Liver Transpl</source>. <year>2001</year>;<volume>7</volume>(<issue>11</issue>):<fpage>937</fpage>–<lpage>942</lpage>.</citation>
</ref>
<ref id="bibr104-0885066610393634">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooney</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Symko</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Groncy</surname>
<given-names>PK.</given-names></name></person-group> <article-title>Hypertensive encephalopathy: complication in children treated for myeloproliferative disorders—report of three cases</article-title>. <source>Radiology</source>. <year>2000</year>;<volume>214</volume>(<issue>3</issue>):<fpage>711</fpage>–<lpage>716</lpage>.</citation>
</ref>
<ref id="bibr105-0885066610393634">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Laningham</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Sandlund</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>RB.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome in children with cancer</article-title>. <source>Pediatr Blood Cancer</source>. <year>2007</year>;<volume>48</volume>(<issue>2</issue>):<fpage>152</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr106-0885066610393634">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Carpintero</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Narbona</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lopez de Mesa</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Arbizu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sierrasesumaga</surname>
<given-names>L.</given-names></name></person-group> <article-title>Transient posterior encephalopathy induced by chemotherapy in children</article-title>. <source>Pediatr Neurol</source>. <year>2001</year>;<volume>24</volume>(<issue>2</issue>):<fpage>145</fpage>–<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr107-0885066610393634">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pihko</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tyni</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Virkola</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Transient ischemic cerebral lesions during induction chemotherapy for acute lymphoblastic leukemia</article-title>. <source>J Pediatr</source>. <year>1993</year>;<volume>123</volume>(<issue>5</issue>):<fpage>718</fpage>–<lpage>724</lpage>.</citation>
</ref>
<ref id="bibr108-0885066610393634">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>R.</given-names></name></person-group> <article-title>Transient Ara-C leukoencephalopathy: MR findings</article-title>. <source>J Comput Assist Tomogr</source>. <year>1996</year>;<volume>20</volume>(<issue>1</issue>):<fpage>161</fpage>–<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr109-0885066610393634">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaughn</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Jarvik</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Hackney</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stadtmauer</surname>
<given-names>EA.</given-names></name></person-group> <article-title>High-dose cytarabine neurotoxicity: MR findings during the acute phase</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1993</year>;<volume>14</volume>(<issue>4</issue>):<fpage>1014</fpage>–<lpage>1016</lpage>.</citation>
</ref>
<ref id="bibr110-0885066610393634">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Arahata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Goto</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1998</year>;<volume>19</volume>(<issue>3</issue>):<fpage>415</fpage>–<lpage>417</lpage>.</citation>
</ref>
<ref id="bibr111-0885066610393634">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rippe</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Schrodt</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Bognanno</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>D’Amour</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Boyko</surname>
<given-names>OB.</given-names></name></person-group> <article-title>Reversible cerebral lesions associated with tiazofurin usage: MR demonstration</article-title>. <source>J Comput Assist Tomogr</source>. <year>1988</year>;<volume>12</volume>(<issue>6</issue>):<fpage>1078</fpage>–<lpage>1081</lpage>.</citation>
</ref>
<ref id="bibr112-0885066610393634">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glusker</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Recht</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>B.</given-names></name></person-group> <article-title>Reversible posterior leukoencephalopathy syndrome and bevacizumab</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>354</volume>(<issue>9</issue>):<fpage>980</fpage>–<lpage>982</lpage>; <comment>discussion 980–982</comment>.</citation>
</ref>
<ref id="bibr113-0885066610393634">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozcan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Hari</surname>
<given-names>P.</given-names></name></person-group> <article-title>Reversible posterior leukoencephalopathy syndrome and bevacizumab</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>354</volume>(<issue>9</issue>):<fpage>980</fpage>–<lpage>982</lpage>; <comment>discussion 980–982</comment>.</citation>
</ref>
<ref id="bibr114-0885066610393634">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bell</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Partington</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Graziano</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Turski</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kornguth</surname>
<given-names>S.</given-names></name></person-group> <article-title>Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus. Correlation with clinical remission and antineurofilament and anticardiolipin antibody titers</article-title>. <source>Arthritis Rheum</source>. <year>1991</year>;<volume>34</volume>(<issue>4</issue>):<fpage>432</fpage>–<lpage>441</lpage>.</citation>
</ref>
<ref id="bibr115-0885066610393634">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gongora</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zunino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Roverano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Paira</surname>
<given-names>S.</given-names></name></person-group> <article-title>Reversible posterior leukoencephalopathy in systemic lupus erythematosus with thrombotic thrombocytopenic purpura</article-title>. <source>J Clin Rheumatol</source>. <year>2007</year>;<volume>13</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr116-0885066610393634">
<label>116</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foocharoen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tiamkao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Srinakarin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chamadol</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sawanyawisuth</surname>
<given-names>K.</given-names></name></person-group> <article-title>Reversible posterior leukoencephalopathy caused by azathioprine in systemic lupus erythematosus</article-title>. <source>J Med Assoc Thai</source>. <year>2006</year>;<volume>89</volume>(<issue>7</issue>):<fpage>1029</fpage>–<lpage>1032</lpage>.</citation>
</ref>
<ref id="bibr117-0885066610393634">
<label>117</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gocmen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ozgen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Oguz</surname>
<given-names>KK.</given-names></name></person-group> <article-title>Widening the spectrum of PRES: series from a tertiary care center</article-title>. <source>Eur J Radiol</source>. <year>2007</year>;<volume>62</volume>(<issue>3</issue>):<fpage>454</fpage>–<lpage>459</lpage>.</citation>
</ref>
<ref id="bibr118-0885066610393634">
<label>118</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kur</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Esdaile</surname>
<given-names>JM.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome—an underrecognized manifestation of systemic lupus erythematosus</article-title>. <source>J Rheumatol</source>. <year>2006</year>;<volume>33</volume>(<issue>11</issue>):<fpage>2178</fpage>–<lpage>2183</lpage>.</citation>
</ref>
<ref id="bibr119-0885066610393634">
<label>119</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lateef</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>AY.</given-names></name></person-group> <article-title>Case reports of transient loss of vision and systemic lupus erythematosus</article-title>. <source>Ann Acad Med Singapore</source>. <year>2007</year>;<volume>36</volume>(<issue>2</issue>):<fpage>146</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr120-0885066610393634">
<label>120</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magnano</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Herrera</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>RD.</given-names></name></person-group> <article-title>Reversible posterior leukoencephalopathy in patients with systemic lupus erythematosus</article-title>. <source>Semin Arthritis Rheum</source>. <year>2006</year>;<volume>35</volume>(<issue>6</issue>):<fpage>396</fpage>–<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr121-0885066610393634">
<label>121</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mavragani</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Vlachoyiannopoulos</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Kosmas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Boletis</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tzioufas</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Voulgarelis</surname>
<given-names>M.</given-names></name></person-group> <article-title>A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion</article-title>. <source>Rheumatology (Oxford)</source>. <year>2004</year>;<volume>43</volume>(<issue>11</issue>):<fpage>1450</fpage>–<lpage>1451</lpage>.</citation>
</ref>
<ref id="bibr122-0885066610393634">
<label>122</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukherjee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McKinstry</surname>
<given-names>RC.</given-names></name></person-group> <article-title>Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging</article-title>. <source>Radiology</source>. <year>2001</year>;<volume>219</volume>(<issue>3</issue>):<fpage>756</fpage>–<lpage>765</lpage>.</citation>
</ref>
<ref id="bibr123-0885066610393634">
<label>123</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozyurek</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Oguz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ozen</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Reversible posterior leukoencephalopathy syndrome: report of three cases</article-title>. <source>J Child Neurol</source>. <year>2005</year>;<volume>20</volume>(<issue>12</issue>):<fpage>990</fpage>–<lpage>993</lpage>.</citation>
</ref>
<ref id="bibr124-0885066610393634">
<label>124</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prasad</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gulati</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>RK.</given-names></name></person-group> <article-title>Is reversible posterior leukoencephalopathy with severe hypertension completely reversible in all patients?</article-title> <source>Pediatr Nephrol</source>. <year>2003</year>;<volume>18</volume>(<issue>11</issue>):<fpage>1161</fpage>–<lpage>1166</lpage>.</citation>
</ref>
<ref id="bibr125-0885066610393634">
<label>125</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Primavera</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Audenino</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mavilio</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cocito</surname>
<given-names>L.</given-names></name></person-group> <article-title>Reversible posterior leucoencephalopathy syndrome in systemic lupus and vasculitis</article-title>. <source>Ann Rheum Dis</source>. <year>2001</year>;<volume>60</volume>(<issue>5</issue>):<fpage>534</fpage>–<lpage>537</lpage>.</citation>
</ref>
<ref id="bibr126-0885066610393634">
<label>126</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheth</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Riggs</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Bodenstenier</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Ketonen</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Ortiz</surname>
<given-names>OA.</given-names></name></person-group> <article-title>Parietal occipital edema in hypertensive encephalopathy: a pathogenic mechanism</article-title>. <source>Eur Neurol</source>. <year>1996</year>;<volume>36</volume>(<issue>1</issue>):<fpage>25</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr127-0885066610393634">
<label>127</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shin</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>YD</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>YW.</given-names></name></person-group> <article-title>Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine</article-title>. <source>J Clin Rheumatol</source>. <year>2005</year>;<volume>11</volume>(<issue>3</issue>):<fpage>164</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr128-0885066610393634">
<label>128</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yong</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Hamour</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>A.</given-names></name></person-group> <article-title>Reversible posterior leukoencephalopathy in a patient with systemic sclerosis/systemic lupus erythematosus overlap syndrome</article-title>. <source>Nephrol Dial Transplant</source>. <year>2003</year>;<volume>18</volume>(<issue>12</issue>):<fpage>2660</fpage>–<lpage>2662</lpage>.</citation>
</ref>
<ref id="bibr129-0885066610393634">
<label>129</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Punaro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abou-Jaoude</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cimaz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ranchin</surname>
<given-names>B.</given-names></name></person-group> <article-title>Unusual neurologic manifestations (II): posterior reversible encephalopathy syndrome (PRES) in the context of juvenile systemic lupus erythematosus</article-title>. <source>Lupus</source>. <year>2007</year>;<volume>16</volume>(<issue>8</issue>):<fpage>576</fpage>–<lpage>579</lpage>.</citation>
</ref>
<ref id="bibr130-0885066610393634">
<label>130</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dy</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Swaroop</surname>
<given-names>VS.</given-names></name></person-group> <article-title>31-year-old woman with confusion and labile behavior</article-title>. <source>Mayo Clin Proc</source>. <year>2002</year>;<volume>77</volume>(<issue>6</issue>):<fpage>557</fpage>–<lpage>560</lpage>.</citation>
</ref>
<ref id="bibr131-0885066610393634">
<label>131</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishimori</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Pressman</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Weisman</surname>
<given-names>MH.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE?</article-title> <source>Lupus</source>. <year>2007</year>;<volume>16</volume>(<issue>6</issue>):<fpage>436</fpage>–<lpage>443</lpage>.</citation>
</ref>
<ref id="bibr132-0885066610393634">
<label>132</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozgencil</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gulucu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yalcyn</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Seizures and loss of vision in a patient with systemic lupus erythematosus</article-title>. <source>Neth J Med</source>. <year>2007</year>;<volume>65</volume>(<issue>7</issue>):<fpage>274</fpage>.</citation>
</ref>
<ref id="bibr133-0885066610393634">
<label>133</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leroux</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sellam</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Costedoat-Chalumeau</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Posterior reversible encephalopathy syndrome during systemic lupus erythematosus: four new cases and review of the literature</article-title>. <source>Lupus</source>. <year>2008</year>;<volume>17</volume>(<issue>2</issue>):<fpage>139</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr134-0885066610393634">
<label>134</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Min</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zwerling</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ocava</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>IH</given-names>
</name>
<name>
<surname>Putterman</surname>
<given-names>C.</given-names></name></person-group> <article-title>Reversible posterior leukoencephalopathy in connective tissue diseases</article-title>. <source>Semin Arthritis Rheum</source>. <year>2006</year>;<volume>35</volume>(<issue>6</issue>):<fpage>388</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr135-0885066610393634">
<label>135</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gijtenbeek</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>van den Bent</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Vecht</surname>
<given-names>CJ.</given-names></name></person-group> <article-title>Cyclosporine neurotoxicity: a review</article-title>. <source>J Neurol</source>. <year>1999</year>;<volume>246</volume>(<issue>5</issue>):<fpage>339</fpage>–<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr136-0885066610393634">
<label>136</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kastrup</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Maschke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wanke</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Diener</surname>
<given-names>HC.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome due to severe hypercalcemia</article-title>. <source>J Neurol</source>. <year>2002</year>;<volume>249</volume>(<issue>11</issue>):<fpage>1563</fpage>–<lpage>1566</lpage>.</citation>
</ref>
<ref id="bibr137-0885066610393634">
<label>137</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Fong</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>FK</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>CL.</given-names></name></person-group> <article-title>Burkitt lymphoma presenting as posterior reversible encephalopathy syndrome secondary to hypercalcaemia</article-title>. <source>Br J Haematol</source>. <year>2009</year>;<volume>146</volume>(<issue>6</issue>):<fpage>584</fpage>.</citation>
</ref>
<ref id="bibr138-0885066610393634">
<label>138</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabbian</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pala</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fallica</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Posterior reversible encephalopathy syndrome in an 87-year-old woman with <italic>Escherichia coli</italic> bloodstream infection</article-title>. <source>Clin Exp Nephrol</source>. <year>2010</year>;<volume>14</volume>(<issue>2</issue>):<fpage>176</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr139-0885066610393634">
<label>139</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belmouaz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Desport</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Leroy</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Posterior reversible encephalopathy induced by intravenous immunoglobulin</article-title>. <source>Nephrol Dial Transplant</source>. <year>2008</year>;<volume>23</volume>(<issue>1</issue>):<fpage>417</fpage>–<lpage>419</lpage>.</citation>
</ref>
<ref id="bibr140-0885066610393634">
<label>140</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koichihara</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hamano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>M.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome associated with IVIG in a patient with Guillain-Barre syndrome</article-title>. <source>Pediatr Neurol</source>. <year>2008</year>;<volume>39</volume>(<issue>2</issue>):<fpage>123</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr141-0885066610393634">
<label>141</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mengiardi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lyrer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Czaplinski</surname>
<given-names>A.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy as the initial manifestation of a Guillain-Barre syndrome</article-title>. <source>Neuromuscul Disord</source>. <year>2009</year>;<volume>19</volume>(<issue>10</issue>):<fpage>709</fpage>–<lpage>710</lpage>.</citation>
</ref>
<ref id="bibr142-0885066610393634">
<label>142</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanelli</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Ougorets</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mifsud</surname>
<given-names>MJ.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome on computed tomography perfusion in a patient on “Triple H” therapy</article-title>. <source>Neurocrit Care</source>. <year>2005</year>;<volume>3</volume>(<issue>1</issue>):<fpage>46</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr143-0885066610393634">
<label>143</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wartenberg</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Parra</surname>
<given-names>A.</given-names></name></person-group> <article-title>CT and CT-perfusion findings of reversible leukoencephalopathy during triple-H therapy for symptomatic subarachnoid hemorrhage-related vasospasm</article-title>. <source>J Neuroimaging</source>. <year>2006</year>;<volume>16</volume>(<issue>2</issue>):<fpage>170</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr144-0885066610393634">
<label>144</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moawad</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Hartzell</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Biega</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Lettieri</surname>
<given-names>CJ.</given-names></name></person-group> <article-title>Transient blindness due to posterior reversible encephalopathy syndrome following ephedra overdose</article-title>. <source>South Med J</source>. <year>2006</year>;<volume>99</volume>(<issue>5</issue>):<fpage>511</fpage>–<lpage>514</lpage>.</citation>
</ref>
<ref id="bibr145-0885066610393634">
<label>145</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozkan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hakyemez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ozkalemkas</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy</article-title>. <source>Neuroradiology</source>. <year>2006</year>;<volume>48</volume>(<issue>12</issue>):<fpage>887</fpage>–<lpage>892</lpage>.</citation>
</ref>
<ref id="bibr146-0885066610393634">
<label>146</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cannon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Caravati</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Filloux</surname>
<given-names>FM.</given-names></name></person-group> <article-title>Hydrogen peroxide neurotoxicity in childhood: case report with unique magnetic resonance imaging features</article-title>. <source>J Child Neurol</source>. <year>2003</year>;<volume>18</volume>(<issue>11</issue>):<fpage>805</fpage>–<lpage>808</lpage>.</citation>
</ref>
<ref id="bibr147-0885066610393634">
<label>147</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sukumaran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>George</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Drobyski</surname>
<given-names>WR.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome as a consequence of high dose steroid administration after autologous PBSCT</article-title>. <source>Bone Marrow Transplant</source>. <year>2010</year>;<volume>45</volume>(<issue>4</issue>):<fpage>779</fpage>–<lpage>780</lpage>.</citation>
</ref>
<ref id="bibr148-0885066610393634">
<label>148</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartynski</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Boardman</surname>
<given-names>JF.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome and cerebral vasculopathy associated with influenza A infection: report of a case and review of the literature</article-title>. <source>J Comput Assist Tomogr</source>. <year>2009</year>;<volume>33</volume>(<issue>6</issue>):<fpage>917</fpage>–<lpage>922</lpage>.</citation>
</ref>
<ref id="bibr149-0885066610393634">
<label>149</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranu Alpay</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Satar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sebe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Demir</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Topal</surname>
<given-names>M.</given-names></name></person-group> <article-title>Unusual presentations of scorpion envenomation</article-title>. <source>Hum Exp Toxicol</source>. <year>2008</year>;<volume>27</volume>(<issue>1</issue>):<fpage>81</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr150-0885066610393634">
<label>150</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Legriel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bruneel</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Spreux-Varoquaux</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus</article-title>. <source>Neurocrit Care</source>. <year>2008</year>;<volume>9</volume>(<issue>2</issue>):<fpage>247</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr151-0885066610393634">
<label>151</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kohrmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huttner</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Storch-Hagenlocher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schwab</surname>
<given-names>S.</given-names></name></person-group> <article-title>Linezolid-induced posterior reversible leukoencephalopathy syndrome</article-title>. <source>Arch Neurol</source>. <year>2007</year>;<volume>64</volume>(<issue>5</issue>):<fpage>746</fpage>–<lpage>748</lpage>.</citation>
</ref>
<ref id="bibr152-0885066610393634">
<label>152</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartynski</surname>
<given-names>WS.</given-names></name></person-group> <article-title>Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2008</year>;<volume>29</volume>(<issue>6</issue>):<fpage>1043</fpage>–<lpage>1049</lpage>.</citation>
</ref>
<ref id="bibr153-0885066610393634">
<label>153</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coughlin</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>McMurdo</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Reeves</surname>
<given-names>T.</given-names></name></person-group> <article-title>MR imaging of postpartum cortical blindness</article-title>. <source>J Comput Assist Tomogr</source>. <year>1989</year>;<volume>13</volume>(<issue>4</issue>):<fpage>572</fpage>–<lpage>576</lpage>.</citation>
</ref>
<ref id="bibr154-0885066610393634">
<label>154</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Striano</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Striano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tortora</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical spectrum and critical care management of Posterior Reversible Encephalopathy Syndrome (PRES)</article-title>. <source>Med Sci Monit</source>. <year>2005</year>;<volume>11</volume>(<issue>11</issue>):<fpage>CR549</fpage>–<lpage>CR553</lpage>.</citation>
</ref>
<ref id="bibr155-0885066610393634">
<label>155</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auer</surname>
<given-names>LM.</given-names></name></person-group> <article-title>The pathogenesis of hypertensive encephalopathy. Experimental data and their clinical relevance with special reference to neurosurgical patients</article-title>. <source>Acta Neurochir Suppl (Wien)</source>. <year>1978</year>;<volume>27</volume>:<fpage>1</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr156-0885066610393634">
<label>156</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kontos</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Navari</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Levasseur</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Rosenblum</surname>
<given-names>WI</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>JL</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Responses of cerebral arteries and arterioles to acute hypotension and hypertension</article-title>. <source>Am J Physiol</source>. <year>1978</year>;<volume>234</volume>(<issue>4</issue>):<fpage>H371</fpage>–<lpage>H383</lpage>.</citation>
</ref>
<ref id="bibr157-0885066610393634">
<label>157</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Koo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names></name></person-group> <article-title>Clinical spectrum of reversible posterior leukoencephalopathy syndrome</article-title>. <source>Pediatr Neurol</source>. <year>2001</year>;<volume>24</volume>(<issue>5</issue>):<fpage>361</fpage>–<lpage>364</lpage>.</citation>
</ref>
<ref id="bibr158-0885066610393634">
<label>158</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mark</surname>
<given-names>AL.</given-names></name></person-group> <article-title>Cyclosporine, sympathetic activity, and hypertension</article-title>. <source>N Engl J Med</source>. <year>1990</year>;<volume>323</volume>(<issue>11</issue>):<fpage>748</fpage>–<lpage>750</lpage>.</citation>
</ref>
<ref id="bibr159-0885066610393634">
<label>159</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scherrer</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Vissing</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>BJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Cyclosporine-induced sympathetic activation and hypertension after heart transplantation</article-title>. <source>N Engl J Med</source>. <year>1990</year>;<volume>323</volume>(<issue>11</issue>):<fpage>693</fpage>–<lpage>699</lpage>.</citation>
</ref>
<ref id="bibr160-0885066610393634">
<label>160</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrara</surname>
<given-names>JL.</given-names></name></person-group> <article-title>Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors</article-title>. <source>J Hematother Stem Cell Res</source>. <year>2000</year>;<volume>9</volume>(<issue>3</issue>):<fpage>299</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr161-0885066610393634">
<label>161</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmauss</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weis</surname>
<given-names>M.</given-names></name></person-group> <article-title>Cardiac allograft vasculopathy: recent developments</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>117</volume>(<issue>16</issue>):<fpage>2131</fpage>–<lpage>2141</lpage>.</citation>
</ref>
<ref id="bibr162-0885066610393634">
<label>162</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savage</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cockwell</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Adu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Howie</surname>
<given-names>AJ.</given-names></name></person-group> <article-title>ABC of arterial and vascular disease: vasculitis</article-title>. <source>BMJ</source>. <year>2000</year>;<volume>320</volume>(<issue>7245</issue>):<fpage>1325</fpage>–<lpage>1328</lpage>.</citation>
</ref>
<ref id="bibr163-0885066610393634">
<label>163</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aird</surname>
<given-names>WC.</given-names></name></person-group> <article-title>The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome</article-title>. <source>Blood</source>. <year>2003</year>;<volume>101</volume>(<issue>10</issue>):<fpage>3765</fpage>–<lpage>3777</lpage>.</citation>
</ref>
<ref id="bibr164-0885066610393634">
<label>164</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faraci</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Heistad</surname>
<given-names>DD.</given-names></name></person-group> <article-title>Regulation of the cerebral circulation: role of endothelium and potassium channels</article-title>. <source>Physiol Rev</source>. <year>1998</year>;<volume>78</volume>(<issue>1</issue>):<fpage>53</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr165-0885066610393634">
<label>165</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beausang-Linder</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bill</surname>
<given-names>A.</given-names></name></person-group> <article-title>Cerebral circulation in acute arterial hypertension—protective effects of sympathetic nervous activity</article-title>. <source>Acta Physiol Scand</source>. <year>1981</year>;<volume>111</volume>(<issue>2</issue>):<fpage>193</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr166-0885066610393634">
<label>166</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edvinsson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Owman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sjoberg</surname>
<given-names>NO.</given-names></name></person-group> <article-title>Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study</article-title>. <source>Brain Res</source>. <year>1976</year>;<volume>115</volume>(<issue>3</issue>):<fpage>377</fpage>–<lpage>393</lpage>.</citation>
</ref>
<ref id="bibr167-0885066610393634">
<label>167</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bleys</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Cowen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Groen</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Hillen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>NB.</given-names></name></person-group> <article-title>Perivascular nerves of the human basal cerebral arteries: I. Topographical distribution</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>1996</year>;<volume>16</volume>(<issue>5</issue>):<fpage>1034</fpage>–<lpage>1047</lpage>.</citation>
</ref>
<ref id="bibr168-0885066610393634">
<label>168</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosengarten</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kaps</surname>
<given-names>M.</given-names></name></person-group> <article-title>Cerebral autoregulation in middle cerebral artery territory precedes that of posterior cerebral artery in human cortex</article-title>. <source>Cerebrovasc Dis</source>. <year>2002</year>;<volume>13</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr169-0885066610393634">
<label>169</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeeman</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Fleckenstein</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Twickler</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>FG.</given-names></name></person-group> <article-title>Cerebral infarction in eclampsia</article-title>. <source>Am J Obstet Gynecol</source>. <year>2004</year>;<volume>190</volume>(<issue>3</issue>):<fpage>714</fpage>–<lpage>720</lpage>.</citation>
</ref>
<ref id="bibr170-0885066610393634">
<label>170</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antunes</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>George</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Boulad</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lis</surname>
<given-names>E.</given-names></name></person-group> <article-title>Posterior leukoencephalopathy syndrome may not be reversible</article-title>. <source>Pediatr Neurol</source>. <year>1999</year>;<volume>20</volume>(<issue>3</issue>):<fpage>241</fpage>–<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr171-0885066610393634">
<label>171</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Servillo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Striano</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Striano</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Posterior reversible encephalopathy syndrome (PRES) in critically ill obstetric patients</article-title>. <source>Intensive Care Med</source>. <year>2003</year>;<volume>29</volume>(<issue>12</issue>):<fpage>2323</fpage>–<lpage>2326</lpage>.</citation>
</ref>
<ref id="bibr172-0885066610393634">
<label>172</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solinas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Briellmann</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Berkovic</surname>
<given-names>SF.</given-names></name></person-group> <article-title>Hypertensive encephalopathy: antecedent to hippocampal sclerosis and temporal lobe epilepsy?</article-title> <source>Neurology</source>. <year>2003</year>;<volume>60</volume>(<issue>9</issue>):<fpage>1534</fpage>–<lpage>1536</lpage>.</citation>
</ref>
<ref id="bibr173-0885066610393634">
<label>173</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lawn</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Laich</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Eclampsia, hippocampal sclerosis, and temporal lobe epilepsy: accident or association?</article-title> <source>Neurology</source>. <year>2004</year>;<volume>62</volume>(<issue>8</issue>):<fpage>1352</fpage>–<lpage>1356</lpage>.</citation>
</ref>
<ref id="bibr174-0885066610393634">
<label>174</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aukes</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Wessel</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Aarnoudse</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Zeeman</surname>
<given-names>GG.</given-names></name></person-group> <article-title>Self-reported cognitive functioning in formerly eclamptic women</article-title>. <source>Am J Obstet Gynecol</source>. <year>2007</year>;<volume>197</volume>(<issue>4</issue>):<fpage>365 e361</fpage>–<lpage>e366</lpage>.</citation>
</ref>
<ref id="bibr175-0885066610393634">
<label>175</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brusse</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Duvekot</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jongerling</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Steegers</surname>
<given-names>E</given-names>
</name>
<name>
<surname>De Koning</surname>
<given-names>I.</given-names></name></person-group> <article-title>Impaired maternal cognitive functioning after pregnancies complicated by severe pre-eclampsia: a pilot case-control study</article-title>. <source>Acta Obstet Gynecol Scand</source>. <year>2008</year>;<volume>87</volume>(<issue>4</issue>):<fpage>408</fpage>–<lpage>412</lpage>.</citation>
</ref>
<ref id="bibr176-0885066610393634">
<label>176</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paul</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Aktas</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Dieste</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Kreitsch</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Zipp</surname>
<given-names>F.</given-names></name></person-group> <article-title>[Relapsing reversible posterior leukoencephalopathy after chemotherapy with cisplatin and 5-fluorouracil]</article-title>. <source>Nervenarzt</source>. <year>2006</year>;<volume>77</volume>(<issue>6</issue>):<fpage>706</fpage>–<lpage>710</lpage>.</citation>
</ref>
<ref id="bibr177-0885066610393634">
<label>177</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finsterer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stollberger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ostermann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zuntner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tscherney</surname>
<given-names>R.</given-names></name></person-group> <article-title>Recurrent posterior reversible encephalopathy syndrome in mitochondrial disorder</article-title>. <source>Blood Press</source>. <year>2009</year>;<volume>18</volume>(<issue>3</issue>):<fpage>1</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr178-0885066610393634">
<label>178</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Onder</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Teomete</surname>
<given-names>U</given-names>
</name>
<etal/>
</person-group>. <article-title>Posterior reversible encephalopathy syndrome in the pediatric renal population</article-title>. <source>Pediatr Nephrol</source>. <year>2007</year>;<volume>22</volume>(<issue>11</issue>):<fpage>1921</fpage>–<lpage>1929</lpage>.</citation>
</ref>
<ref id="bibr179-0885066610393634">
<label>179</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finsterer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schlager</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kopsa</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wild</surname>
<given-names>E.</given-names></name></person-group> <article-title>Nitroglycerin-aggravated pre-eclamptic posterior reversible encephalopathy syndrome (PRES)</article-title>. <source>Neurology</source>. <year>2003</year>;<volume>61</volume>(<issue>5</issue>):<fpage>715</fpage>–<lpage>716</lpage>.</citation>
</ref>
<ref id="bibr180-0885066610393634">
<label>180</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leeman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fontaine</surname>
<given-names>P.</given-names></name></person-group> <article-title>Hypertensive disorders of pregnancy</article-title>. <source>Am Fam Physician</source>. <year>2008</year>;<volume>78</volume>(<issue>1</issue>):<fpage>93</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr181-0885066610393634">
<label>181</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sibai</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dekker</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kupferminc</surname>
<given-names>M.</given-names></name></person-group> <article-title>Pre-eclampsia</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>365</volume>(<issue>9461</issue>):<fpage>785</fpage>–<lpage>799</lpage>.</citation>
</ref>
<ref id="bibr182-0885066610393634">
<label>182</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coppage</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Sibai</surname>
<given-names>BM.</given-names></name></person-group> <article-title>Treatment of hypertensive complications in pregnancy</article-title>. <source>Curr Pharm Des</source>. <year>2005</year>;<volume>11</volume>(<issue>6</issue>):<fpage>749</fpage>–<lpage>757</lpage>.</citation>
</ref>
<ref id="bibr183-0885066610393634">
<label>183</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sekine</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Miura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>T.</given-names></name></person-group> <article-title>Children’s toxicology from bench to bed—Drug-induced renal injury (1): The toxic effects of ARB/ACEI on fetal kidney development</article-title>. <source>J Toxicol Sci</source>. <year>2009</year>;<volume>34</volume>(<issue>suppl 2</issue>):<fpage>SP245</fpage>–<lpage>SP250</lpage>.</citation>
</ref>
<ref id="bibr184-0885066610393634">
<label>184</label>
<citation citation-type="journal">
<collab collab-type="author">Treatment of convulsive status epilepticus</collab>. <article-title>Recommendations of the Epilepsy Foundation of America’s Working Group on Status Epilepticus</article-title>. <source>JAMA</source>. <year>1993</year>;<volume>270</volume>(<issue>7</issue>):<fpage>854</fpage>–<lpage>859</lpage>.</citation>
</ref>
<ref id="bibr185-0885066610393634">
<label>185</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knake</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hamer</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Rosenow</surname>
<given-names>F.</given-names></name></person-group> <article-title>Status epilepticus: a critical review</article-title>. <source>Epilepsy Behav</source>. <year>2009</year>;<volume>15</volume>(<issue>1</issue>):<fpage>10</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr186-0885066610393634">
<label>186</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Euser</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Cipolla</surname>
<given-names>MJ.</given-names></name></person-group> <article-title>Magnesium sulfate for the treatment of eclampsia: a brief review</article-title>. <source>Stroke</source>. <year>2009</year>;<volume>40</volume>(<issue>4</issue>):<fpage>1169</fpage>–<lpage>1175</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>